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Abstract 
Various statistical methods are utilized in the determination of reliable cholesterol 
measurements via the Reflotron desk-top analyzer. The analysis presented in this research 
concerns data from the Worksites, Occupational Nurses, and Cholesterol Change 
Program, a study consisting of volunteers at various worksites in Southern Massachusetts 
and Rhode Island. 
Accuracy and precision tests are utilized to determine reliability of cholesterol 
measurements. The initial lot testing of reagent strips gives estimates of bias resulting 
from Reflotron cholesterol measurement. Regression analysis techniques are employed to 
adjust for this bias. The accuracy testing failed to fall within the guidelines set by the 
National Cholesterol Education Program (bias<=5% ). A negative bias exists between the 
Reflotron and reference laboratory values when measuring total blood cholesterol. 
However, lots ofreagent strips were chosen to proceed to the next round of testing since 
resulting cholesterol measurements can be adjusted for bias. 
The second phase of testing involves analysis of experimental precision. The 
design of the experiment entails all apparent sources of variation inherent to the 
cholesterol measurement process by Reflotron determination. The precision testing was 
successful in meeting the NCEP guidelines (CV<=5%), and information concerning the 
various random components was collected. Estimates of variance components are utilized 
in the construction of tolerance intervals to be used for quality control procedures in the 
field experiment consisting of worksite-wide cholesterol screening. A standardized 
method of reporting accuracy termed the maximum percent error is introduced and 
employed to compare various trials of the experiment, along with the calculation of 
coefficients of variation. Approximate confidence intervals are constructed for each 
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variance component and for the overall variability in the experimental model. This gives a 
range of variability associated with the process, and an idea of which components 
contribute the greatest source of variation to the experimental model. 
The final calculations are for the adjustment of cholesterol measurements in the 
field experiment. The purpose is to utilize the quality control levels to determine the 
estimated true cholesterol values of participants in the study. Prediction intervals are then 
constructed to determine a range of values within which an individual's true cholesterol 
level falls . Thus, if misclassification of individual true cholesterol measurements occurs, 
the prediction interval gives information concerning the risk category to which an 
individual is likely to belong. Remedial measures are recommended for future testing. 
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I. INTRODUCTION 
Coronary heart disease (CHD) is the leading cause of death in the United States l _ 
Heightened awareness of the importance of cholesterol as a primary modifiable risk factor 
for heart disease has increased the number of individuals having their cholesterol levels 
measured. For each 1 % decreases in total blood cholesterol, the rate of coronary heart 
disease is reduced by 2%2. An estimated 36% of the population has hypercholesterolemia 
as defined by the National Cholesterol Education Program (NCEP). An estimated 41 % of 
American adults have cholesterol levels which justify further testing and possible 
treatment3 . When treated with diet modification and/or drug therapy, individuals with 
high blood cholesterol can decrease their risk of heart disease. The NCEP recommends 
that all persons over the age of twenty have their cholesterol levels measured at least once 
every five years, and those with high cholesterol (>240 mg/di) receive treatment to lower 
their cholesterol levels. In response, "simple" cholesterol testing procedures have become 
common with the development of portable desk-top analyzers which allow for 
inexpensive, fast, accurate measurements of serum cholesterol. Widespread public 
screening has become common place and allows for large numbers of individuals with high 
blood cholesterol levels to be identified and alerted. 
The Worksites, Occupational Nurses, and Cholesterol Change Program is a study 
affiliated with the Memorial Hospital in Pawtucket, Rhode Island designed to address 
many specific aims. One of the most important of these aims is to determine whether 
occupational nurses within a worksite (Internal) are more effective in lowering total blood 
cholesterol than technicians employed by an outside screening organization (External) to 
direct cholesterol screening, educate individuals about cholesterol, and conduct referral 
programs for individuals at risk. Another important goal is to determine if automated 
cholesterol assessment and feedback of suggested behavior changes (Rl) is as effective in 
reducing CHD modifiable risk factors as a face-to-face delivery of these recommendations 
in a brief I 0-12 minute counseling session (FF) . 
The following is an overview of the research design implemented in the Worksites, 
Occupational Nurses, and Cholesterol Change Program. Twenty-five worksites in 
Southern Massachusetts and Rhode Island with full-time occupational nurses were 
recruited and then assigned randomly to one of five experimental units, each condition 
consisting of five worksites (See Appendix A, Figure 1 ). Cholesterol measurements were 
taken and recorded for individuals within each worksite involved in the study to obtain 
baseline data. The cholesterol measurements were taken utilizing a Reflotron portable 
desk-top analyzer. A random sample of the employees within each worksite were tested 
at six-month and twelve-month follow-up . 
The 10 worksites which fall into the Internal condition employed the occupational 
nurse(s) within each worksite to conduct the cholesterol Screening, counseling, and 
Referral Events (SCOREs ). The 10 worksites within the External condition, however, 
had cholesterol SCOREs implemented by project staff, persons hired and trained for this 
research study. All persons involved in conducting SCOREs were trained in the same 
manner. Also, every employee participant received a nutrition kit, literature concerning 
various foods and their cholesterol contents. This should help individuals modify their 
eating habits to lower total blood cholesterol. 
One group of 5 worksites within the Internal condition (Internal-FF) and one 
group of 5 worksites within the External condition (External-FF) were given face-to-face 
cholesterol education and referral consultations with participants based upon individual 
risk factor analysis. These meetings take approximately 10-12 minutes. The risk factor 
analysis is based upon total blood cholesterol, blood pressure, self-reported eating patterns 
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(based on responses to a food frequency/dietary survey), and other cardiovascular disease 
(CVD) risk factor status (i .e. age, gender, smoking status, body mass index). 
In the remaining 5 Internal and 5 External condition worksites (Internal-RT & 
External-RI), each participant completed a questionnaire card which was then inserted 
into a RT2000 micro-computer optical scanner. The respondent then obtained a computer 
printout which contains at most 7 behavioral changes for lowering his/her risk of heart 
disease. These suggested changes are ordered from most to least important. 
The final conclusions drawn at the end of the study are based on the assumption 
that the cholesterol measurements taken on individuals are reliable. There are two 
components that determine the accuracy of measurements. These are precision and bias. 
Precision is defined as the closeness of repeated measurements on the same item. Bias is 
defined as the systematic error in repeated measurements, the difference between the true 
target value and the measurement value which can be corrected by calibration with 
standards. The goal of this work is to determine how accurate these cholesterol 
measurements are, and how they should be adjusted in the final stage so that they actually 
represent the true cholesterol values of individuals in the study. Much has been reported 
on the accuracy of Reflotron obtained cholesterol measurements in various experiments. 
Some experiments report reliable results were obtained with the Reflotron desk-top 
analyzer (within NCEP guidelines), while other experiments report the opposite. 
Hence, we need to know the process by which the cholesterol measurements are 
taken. The Reflotron is an electrochemical reflectance photometer that measures 
chromatic changes in blood which are produced by various chemical constituents. 
Reflectance is measured with a reference beam and an Ulbricht sphere located within the 
instrument. Two detectors in the optical module compare the emitted light from three 
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diodes with the reflected light from the reagent tab. The amount of reflected light is 
inversely proportional to the cholesterol concentration in the sample, and a signal 
processor transmits the associated voltage to a digital display4. The Reflotron system of 
cholesterol measurement works in the following manner. Approximately a 30-µL aliquot 
of human blood or sera is pipetted onto an application pad on a reagent strip. "The top 
layer of the glass-fiber pad retains erythrocytes when whole blood is used, allowing the 
plasma to diffuse to an adjacent reaction area. The reagent system is impregnated into the 
membranous layer on the strips ." When the reagent strip is inserted into the Reflotron 
machine, contact occurs between the reagent and sample layers which starts a chemical 
reaction. This reaction is given by the following : 
cholesterol esters + H20 cholesterol esterase cholesterol + RCOOH 
cholesterol + 0 2 cholesterol oxidase cholest-4-ene-3-one + H202 
H202 + 3,3',5,5'-tetramethylbenzidine peroxidase oxidized benzidine 
(blue) + H20 
It has been previously documented that variability exists between manufactured 
lots of reagent strips6. This is the reason for the initial reagent strip lot testing scheme. 
Since each lot of reagent strips is only ''good" for so long, each lot having a specific 
expiration date, testing is necessary to obtain a lot of reagent strips for worksite-wide 
cholesterol testing at baseline, 6-month follow-up, and 12-month follow-up . 
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II . ACCURACY TESTING 
In the Worksites, Occupational Nurses, and Cholesterol Change Program, the 
importance of reliable cholesterol measurements is imperative. When measuring an 
individual's cholesterol value by a Reflotron desk-top analyzer, many sources of variation 
are inherent to the process. For instance, no two lots ofreagent strips are identical. 
Viewed from a long-term perspective, these differences contribute to total random error6. 
The initial accuracy testing was performed in order to determine which lot of reagent 
strips give the best, most accurate results. This was done by determining what percentage 
of Reflotron-obtained values for each lot of reagent strips fell within specific guidelines set 
by the NCEP. The NCEP has set goals of reducing allowable bias to <=5%. However, 
the minimal guidelines utilized in this research are set at 14.2% and 8.9% of the target or 
true value. 
In this initial lot testing, approximately 20-30 volunteers are utilized. Each 
individual has his/her total blood cholesterol measured three times, twice by Reflotron and 
once by venous blood sample. The procedure for each individual volunteer is as follows . 
To obtain the two Reflotron-based cholesterol measurements, an individual has his/her 
finger lanced by a technician in order to produce a blood specimen. The technician 
captures the blood sample in a glass capillary tube and transfers it to a reagent strip from a 
specific lot of reagent strips. This reagent strip is then inserted into a Reflotron machine 
which gives a digital display of the individual's cholesterol value in 175 seconds. This 
value is then recorded by the technician. A second specimen of blood is taken, either from 
the same lance-induced wound or from a new one. It is then transferred in the same 
manner to a reagent strip from the second lot of reagent strips being tested and analyzed 
on a second Reflotron machine to obtain the second "finger-stick" based cholesterol value. 
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Note that already a second form of variability has been introduced into the system, 
machine-to-machine variability. To counter act this added variability, approximately the 
first half of the volunteers' first finger-stick values are obtained with reagent strip A in 
machine 1 and the second half of the volunteers' first finger-stick values are obtained with 
reagent strip A in machine 2. Likewise, the second finger-stick values are obtained for the 
first half of the volunteers with reagent strip B in machine 2 and for the second half of the 
volunteers with reagent strip B in machine 1. 
Finally, to obtain the third cholesterol value, a venous blood sample is drawn and 
analyzed at the Center for Disease Control standardized laboratory at Miriam Hospital. 
The results for an individual's cholesterol measurement via venous blood sample take 
approximately one to two weeks to obtain. The cholesterol values are taken as the true 
cholesterol value or "gold standard" for each person since the reliability of these estimates 
is great. The procedure for analysis is found in Appendix A, Figure 2. These gold 
standard measurements are made up of three components. Cholesterol values are divided 
into LDL cholesterol (bad), HDL cholesterol (good), and trigycerides. 
A. Percent Differences 
One can get an estimate of the accuracy of an individual lot of reagent strips by 
calculating the percent differences between the finger-stick and gold standard values. This 
provides a measure of the bias in Reflotron obtained results and gives a criteria in which to 
compare various lots of reagent strips. A detennination can be made as to what percent of 
cholesterol values fall within the minimal NCEP guidelines of 14.2% and 8.9% for each lot 
of reagent strips. This type of procedure is utilized first to get baseline data on the 
accuracy of a lot of reagent strips to detennine whether further reliability testing is 
warranted. Then, this same procedure is employed every time a new lot of reagent strips 
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is needed. Since the lots have only a 8-10 month shelf-life, new lots are necessary for 
baseline, 6-month follow-up, and 12-month follow-up cholesterol measurements at each 
worksite in the study. When protocol is followed and variability between experiments is 
kept minimal, reliable results can be obtained. 
For example, the first lot testing in February, 1993 consisted of 19 volunteers. The 
two initial lots of reagent strips compared were lot 941 and lot 942. The data for this 
initial lot testing is located in Appendix B. Scatter plots of the bias of Reflotron obtained 
cholesterol values versus the gold standard values can be found in Figures 1, 2, 3. For 
every experiment, the scatter plot implies a negative bias; the Reflotron results consistently 
underestimate the true cholesterol values. 
Let Y,1 (i= l ,2; j=l ,2, .. .,n) denote the ith fingerstick measurement (obtained with a 
reagent strip from a particular lot) on the jth volunteer, and let X 1 denote the gold 
standard value of the jth volunteer. In this example, let i= 1 if reagent strip from lot 941 
and let i=2 if reagent strip from lot 942. 
To calculate the percent difference between the Reflotron obtained cholesterol 
values and the gold standard values, standardization is required as follows: 
Y -X V% = I) J *100 
X 1 
Results of accuracy for all initial lot testing are located in Table 1. 
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In this example, 100% of the Reflotron observations fall within± 14.2% of the 
gold standard values regardless of the lot of reagent strip utilized. However, lot 941 
faired slightly better with 84.2% of its fingerstick values falling within ±8.g<>/o as opposed 
to lot 942 with 78 .9% of its fingerstick values falling within ±8.9%. Both of these lots of 
reagent strips are fairly accurate and warrant further testing. 
B. Simple Linear Regression 
Another method of determining the more accurate or "better" lot of reagent strips 
is to employ rudimentary regression techniques. This analysis is utilized later in this 
research when discussion turns to adjustment of fingerstick values in the worksite-wide 
cholesterol screening program. It is expected that the Reflotron values are exactly the 
same as the gold standard values if everything works perfectly. Thus, the relationship 
between the methods of cholesterol measurement should be: 
Yij = x j 
given no sources of variation. However, the measurements obtained from the fingerstick 
method are liable to many sources of variation, and the relationship between the Reflotron 
values and the gold standard values can be modeled as 7: 
It is expected that the intercept parameter Po is close to 0 and the slope parameter /3., is 
close to 1. The results ofregression analysis can be located in Table 2. 
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For example, in the initial lot testing of reagent strips, the .experiment included lots 
941 and 942 . The results from the regression analysis are: 
Lot 941: 
Lot 942: 
Y = 5.62+0 .94X 
Y = -26.39+1.08X 
In the first lot testing, both lot 941 and lot 942 appear to be fairly accurate with 
parameters close to target values. Hence, both lots of reagent strips warrant further 
testing. Whichever fairs well in the next round of testing is to be used in the worksite-
wide screening process. 
In August, 1993 a new lot of reagent strips is needed. The shelf-life oflot 941 
(after all the testing, the chosen reagent strip lot used to collect baseline worksite-wide 
cholesterol values) is quickly approaching. The second lot testing experiment was run 
with reagent strips from lot 941 and lot 943 and consisted of 33 volunteers. The gold 
standard value of one individual is missing so calculations are based on a sample size of 
32. Of those measured with reagent strips from lot 941 , 60.6% fell within ±8.9% and 
75 .8% fell within± 14.2% of the true value. Lot 943 , unfortunately, failed miserably in 
comparison with only 27.3% within ±8.9% and 72 .7% within± 14.2%. The regression 
results restate this result . Lot 941 again has a slope close to 1 whereas lot 943 grossly 
underestimates the gold standard values. Thus, lot 943 is not acceptable, and no further 
testing of it is planned. 
Still searching for a new lot of reagent strips, the third initial lot testing is 
conducted with lot 941 and lot 564. The values obtained from lot 941 are again 
decreasing in accuracy. Now only 43 .3% of the fingerstick observations are within 
±8.9% and 73 .3% within± 14.2%. Thankfully, lot 564 appears promising with 70.0% 
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within ±8.9% and 100% within± 14.2%. Again, the regression results support this 
finding, and Jot 564 moves on to the next round of testing (lot 564 is the lot chosen, after 
all reliability testing is performed, to collect 6- month follow-up worksite-wide cholesterol 
values) . 
Notice that the accuracy oflot 941 has decreased from the initial February, 1993 
experiment to the August, 1993 experiment. This can possibly be attributed to the fact 
that the expiration date for lot 941 is approaching. Unfortunately, the rate at which 
accuracy has decreased is not known. The accuracy of the lot ofreagent strips may have 
delined steadily since the manufacturing date, or perhaps it fell sharply at some particular 
point in time. This aspect of reagent strip accuracy should be montiored further. 
The overall mean percent differences between the desktop results and the reference 
Jab results were not all within the established NCEP guidelines for accuracy (5 .0%). Only 
the February, 1993 lot testing of 941 and 942 meets the guidelines with -3 .6% and -5 .1 % 
respectively. Lot testing of 564 resulted in an overall mean percent difference of -6.5% 
which is outside the guidelines, yet it still appears to be a viable Jot of reagent strips. 
Finally, it is concluded that all lots of reagent strips result in negatively biased 
cholesterol values, estimates lower than the gold standard values. Thus, Reflotron 
obtained cholesterol measurements underestimate the true cholesterol value of an 
individual. How much each lot of reagent strips underestimates the true value varies. 
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III. PRECISION TESTING 
A Design of Experiment 
In the second stage of lot testing reagent strips, precision of the process is to be 
assessed. The goal of this testing is to determine how well this cholesterol screening 
identifies persons at risk of high cholesterol based on the measurement obtained from the 
Reflotron. The experiments are run in order to set tolerance limits for the purpose of 
quality control checks when performing mass cholesterol screening at worksites. There 
are several sources of variability associated with cholesterol measurement via the 
Reflotron desk-top analyzer. Sources of variability are any factors in the experiment that 
may cause repeated measurements on the same item to differ. In these experiments, 
frozen samples of sera are utilized here as opposed to an individual's whole blood. Each 
vial of frozen sera is actually a pool of approximately 30 different whole blood samples. 
Hence the exact cholesterol concentration is not known. However, the range in which 
each vial's cholesterol value should fall is known. The ranges are defined as high (>240 
mg/dl), medium (200-239 mg/di), and low (<200 mg/di). The assigned technician extracts 
the sera sample from a specific tube with a glass capillary tube and transfers it onto a 
reagent strip from a specific vial of strips. The strip is then inserted into a designated 
Reflotron machine. Finally, the cholesterol measurement obtained is recorded. 
Let the pool the sera belongs to be factor P, the round of experimentation factor 
R, and the sample of sera from a specific tube factor S. Since each round is different for 
each pool of sera, factor R is nested within factor P. Also, factor S is nested within factor 
R and P since each sample of sera is unique for each round within each pool. Let the 
machine analyzing the sera sample be factor M and the technician conducting the 
experiment be factor T. Let the vial of reagent strips used to test the sera sample be factor 
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v. Lastly, let & denote the random error in the study. Tlus is the catch-all, everything 
else on explained by the model. Since there should be no significant interactions between 
factors, no crossed effects are in the model. 
The type of the effects are of importance in the model. They are either fixed or 
random. When deciding whether a set of effects is fixed or random, the question is that of 
inference and consequently how the levels are chosen8. If inferences are to be drawn from 
these data about only the levels of the factor in the experiment, then the effect in question 
is a.fixed effect. Otherwise, if inferences are to be drawn from these data about not only 
the levels of the factor represented in the experiment, but also those levels from an infinite 
set of factor levels, of which only a random sample occur in the data, then the effect is a 
random one. 
The factor P only has three possible levels. Sera samples fall into the following 
ranges: low (less than 200mg/dl), medium (200-239mg/dl), high (240 mg/di or above). 
Each of these values is considered in the experiment. P (pool) is a fixed effect. 
The round of experimentation within each pool has only two levels (1 ,2) in this 
testing procedure but the number oflevels could be infinite. We have no specific interest 
in the difference between the two rounds and any other rounds. Hence, R (round) is a 
random effect . 
Similarly, the samples of sera utilized within each round and pool are randomly 
taken from a population of samples. There is no interest in the difference between any of 
the specific sera samples and so S (sample) is a random effect. 
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M (machine) is a random effect . The machines utilized in the experiment are only 
a small, random subset of all possible Reflotron machines which could have been 
employed. 
The technicians conducting the experimental design are a random sample from a 
population of possible technicians. There is no specific interest in evaluating the difference 
between any one of the technicians in the experiment and any other of them. Thus, factor 
T (technician) is a random effect. 
V (vial of strips) is also a random effect. The vials of reagent strips within a 
specific lot used in the testing are a random subset of all possible vials of strips which 
could have been utilized. 
The model consists of a single fixed effect and five random effects. This is referred 
to as a mixed model. A single cholesterol measurement is taken for each treatment level 
combination, but each factor level does not contain the same number of observations. For 
example, in the August experiment of lot 94 I, machine #I and machine #2 were employed 
five different times while machine #3 was used six times. Thus, the model is said to be 
unbalance<fa. 
Note that in the first precision testing done in February 1993, the factor V was not 
included in the design. After the initial February lot testing, it came to be known that 
different vials of reagent strips were utilized in the experiment, another source of variation 
to be accounted for. The strip vial effect was added to the model to help further partition 
the variance. 
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The nested, unbalanced, mixed model for the February, 1993 experiments is given 
And, the nested, unbalanced, mixed model for the August, 1993 and subsequent 
experiments is given by: 
y ijkmnpq = P, + R j(i) + sk(ij ) +Mm+ 1~ +VP+ eq(1jkmnp ) 
where P, are the fixed pool effects, R1(i ) are the random round (within pool) effects, Sk (ij ) 
are the random sera samples effects (within round and pool), Mm are the random machine 
effects, T,, are the random technician effects, VP are the random strip vial effects, and 
e q(1J1a"" > are the random error effects. Normality of random effects is assumed. Thus, we 
assume R j(i ) > sk(1J)> Mm • T n, VP , and eq(1jkmn ) are normally distributed with expectations 
zero and variances ~ , ifs , a!1 , a;. , a?,, , and 0-:, respectively. The variances associated 
with these random effects are also termed variance components and are analyzed in later 
evaluation in the calculation of tolerance limits, maximum percent errors, and confidence 
intervals for not only the variance components themselves but for the total variability of 
the model (observation). 
B. Generation of Experimental Design 
Using SAS proc plan, the experiment is designed as follows . Each time the 
experiment is to be run, the following SAS code is modified to produce the matrix of 
factor levels which will be available on the day of sera testing. 
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proc plan seed=3091966; 
factors tech=3 ordered round=2 ordered 
pool=3 cyclic sample=S ordered; 
output out=who 
tech cvals=('Lynn' 'Jen' 'Cat') random 
pool cvals=('High' 'Med' 'Low') random; 
factors tech=3 ordered round=2 ordered 
machine= 15 random; 
output out=which; 
factors tech=3 ordered round=2 ordered 
pool=3 cyclic strvial=S random; 
output out=what; 
data design; 
merge who which(keep=machine) where(keep=strvial); 
data final ; 
set design; 
by tech round pool notsorted; 
if first.tech then tube=O; 
if first. pool then tube+ 1; 
if first.tech then sequence=O; 
sequence+ 1 ; 
proc print; 
by tech notsorted; 
pageby tech; 
id sequence; 
var round tube pool sample machine strvial ; 
end; 
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Proc plan constructs designs and randomizes plans for nested and crossed 
experiments. Randomization is used both to neutralize the effect of any systematic biases 
that may be involved in the design as well as to provide a basis for the assumptions 
underlying the anaJysis. Proc plan generates designs by generating a selection of factor 
levels (for a given factor) for all combinations oflevels for factors which precede it 10. 
The proc plan statement is followed by the option seed which is a 5-,6-, 7-digit number 
used to start the pseudo-random number generator for random selection of factor levels. 
Selection of factor levels can be accomplished in three different manners for each factor in 
the design after the number of factor levels has been specified for every effect. 
1. RANDOM selection -- levels are chosen in random 
order based on uniform pseudo-random order. 
2. ORDERED selection -- levels are chosen in a standard order 
repeatedly. 
3. CYCLIC selection -- levels are chosen by cyclically permuting the 
levels of the previous selection.10 
After generating a design, it is stored in an output SAS data set using the output 
statement. Values are assigned to factor levels whether they be numerical (nvals) or 
character strings (cva/s) . Various generated plans are then merged together and a highly 
structured design is realized. The design matrix can then be reviewed and printed. Refer 
to Appendix C for the design matrices for aJl precision testing of reagent strips. The 
specific factor levels and values for each precision experiment designed are located in 
Table 3. 
Modifying the initiaJ seed vaJue results in different plans. A constant seed vaJue, 
however, generates the same plan repeatedly other things being equal. 
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The technjcians then run the experiment as designed following strict protocol. 
First the Reflotrons' optical eyes are checked to insure that the machines are reporting 
cholesterol values in the "correct" range. With a reagent strip from a lot of previously 
analyzed strips, a quality control (QC) check is performed. A sample of high sera and a 
sample oflow sera are measured separately. If both initial sera samples are within their 
respective 95% tolerance limits previously set, the machine is accepted and the optical eye 
cleaned. If either sample fails by falling outside of known 95% tolerance limits, another 
sample from the failed pool is measured. If the quality control check falls outside of the 
limits in the same direction, the malfunctioning Reflotron machine is replaced with a back-
up. If the resulting value is within the limits, the experiment continues as mentioned 
above. Once all machines are calibrated, strip testing begins. Generally, for the design 
implemented, this testing process takes approximately 1-1. 5 hours to complete. 
Cholesterol values are digitally displayed by the Reflotron 175 seconds after 
insertion of the specified sera sample on the specified reagent strip and recorded by the 
selected technician. At the termination of the experiment, the optical eye in each machine 
is cleaned once again. 
After witnessing a precision experiment, I have a recommendation to make. The 
technicians transfer the sera sample to ·a reagent strip with a glass capillary tube. Each 
technician has his/her own vial of capillary tubes to use. However, since one technician 
emptied his/her vial of capillary tubes before the completion of the experiment, he/she 
"borrowed" some from another technician. Each of these vials of capillary tubes has an 
expiration date. This suggests that the vial of capillary tubes used could quite possibly be 
an additional source of variation and should be added to the experimental model. 
C. Analysis of Experiment 
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After inputting the results of the precision experiment and merging these results 
with the generated experimental design, the following SAS code is run to generate the 
appropriate ANOV A table (Table 7), calculate expected mean squares (Table 7), estimate 
the factor-level means of the fixed effect (Table 3) and estimate the variance components 
(Table 4). 
proc glm; 
class pool round sample machine tech strvial; 
model chol =pool round(pool) sample(round pool) machine tech strvial; 
random round(pool) sample(round pool) machine tech strvial I test; 
lsmeans pool; 
proc varcomp method=reml; 
class pool round sample machine tech strvial; 
model chol = pool round(pool) sample(round pool) 
machine tech strvial I fixed= 1; 
The variables are defined as follows: 
pool = low, medium, high 
round(pool) = 2 rounds within each pool 
sample(round pool)= 5 samples of blood sera in each tube for each 
round within each pool 
machine = Reflotrons used 
tech = 3 technicians conducting experiment 
strvial = 5 vials of reagent strips from lot being measured 
chol = cholesterol value obtained from the Reflotron, our dependent 
variable 
Variance components can be estimated in several ways. The four common 
methods of variance component estimation arel 1: 
1. ANOV A Estimation (TYPE 1) 
2. Minimum Variance Unbiased Estimation (MINQUE or 
MIVQUE(O) 
3. Maximum Likelihood Estimation (ML) 
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4. Restricted Maximum Likelihood Estimation (REML) 
ANOV A estimation is the easiest to compute relative to the other methods 
mentioned, but there are inherent disadvantages. Not only are negative estimates possible, 
but the estimates lack distributional properties. And, there is no useful way to compare 
different applications of ANOV A methodology. 
The second method MJVQUE(O) gives the minimized generalized variance, and no 
distributional properties of the random effects are needed. However, estimators obtained 
by this method "are functions of a priori values used in place of the variance components 
in the estimation procedure itself' and this procedure "has what we deem to be a serious 
deficiency: the minimality property applies only at those a priori values" 11 . 
Maximum Likelihood estimation of variance components is based upon normality 
assumptions. The random effects have means and variances defined and are distributed 
normally. Calculating ML estimates involves iterative calculations which, before the 
existence of computers and computing packages, were difficult if not impossible to 
compute. 
The final method of variance component estimation is REML. Restricted 
Maximum Likelihood is ML on certain linear combinations of the data rather than on the 
data themselves. The idea behind it is to maximize that part of the likelihood which is 
invariant to the fixed effects in the model. One advantage to REML is that it "takes 
account of the implicit degrees of freedom associated with the fixed effects, whereas ML 
does not" 11 _ 
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In this study, REML is the method of choice when computing variance component 
estimates. Negative estimates are not a problem when utilizing REML, and it seems to 
give estimates in keeping with those obtained from the other methods available. Refer to 
Table 4 for variance component estimates computed by each of the afore mentioned 
methods for each of the precision experiments run. 
D. Computation of Tolerance Intervals 
The results of the precision testing are used to help maintain reliable cholesterol 
screening results in the field . When testing begins at worksites, certain quality control 
protocol must be followed. To determine if a Reflotron machine is suitable for usage in 
the field experiment or requires adjustment, a sera sample from each of the high and low 
pool will be tested. If the corresponding cholesterol values are within the allowable 
ranges, the machine is acceptable. These allowable ranges of variation are termed 
tolerance intervals. Tolerance limits are derived using REML variance estimates from the 
experiments designed to partition the variance into the following components: Round, 
Sample, Machine, Technician, Strip Vial (added after the February lot testing), 
Measurement Error. For each pool of sera, the (1- a)% tolerance limits are constructed 
for the February lot testing as 12: 
and for the August and subsequent lot testing as: 
P; ±Za12 ~o; +~+~ + cl,.+ clv + ci; 
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where P, is the overall mean cholesterol value for pool i, i=High, Medium, Low (Table 3). 
See Table 5 for 95% tolerance limits for each of the experiments run. 
To compute tolerance limits for lot 941 and lot 942 in the February, 1993 
precision testing case, the tolerance limits were derived using pooled variance components 
for the two experiments per lot. Since the technician variation decreased dramatically 
from the first to the second run of the lot 941 and lot 942 experiments, the technician 
variance component, however, was estimated based on the results from the first run of the 
experiment to be conservative(*). For example, the computations for a 95% tolerance 
interval on lot 941 is actually based upon the following estimates of the variance 
components. 
Random Effect: Round Sample Machine Technician Error Total 
* 
Estimate: 4.88 0 1.89 9.50 21.42 37.69 
The overall mean cholesterol level for each pool of sera, P, , were taken from the 1st lot 
941 testing which resulted in the larger of the estimates. Since it is known that the reagent 
lots produce cholesterol measurements lower than the actual cholesterol measurement, the 
P; from the 1st testing oflot 941 are considered the most appropriate. Hence, the 95% 
tolerance limits for lot 941 for each pool are: 
High: 
Medium: 
Low: 
239.75 ±1.96J37.69 ~(227,252) 
214.86±1. 96J37.69 ~(202, 227) 
157.28 ± 1.96J37.69 ~(145, 170) 
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These are the tolerance limits used for quality control checks in the field experiment when 
using reagent strips from lot 941 to conduct the worksite-wide cholesterol screening. 
Since the Reflotron displays cholesterol values as whole numbers, the lower tolerance limit 
has been rounded down to the next whole number, and the upper tolerance limit has been 
rounded up to the next whole number. 
In the February, 1993 precision testing, the technician component is significant in 3 
of the 4 experiments run. When the random effect for vial of strips is added as a source of 
variation in the August, 1993 precision testing, this variance component is now 
significantly large, and the technician component is not. This suggests that perhaps strip 
vial and technician were confounded previously. The tolerance intervals computed from 
this experiment are wider than those from the February, 1993 experiment. Recall that the 
shelf-life oflot 941 is quickly approaching the expiration date. In the lot 941 testing, this 
random strip vial component is estimated to be more than three times greater than the 
measurement error. This gives strong indication of variability within a specific lot of 
reagent strips. However, this problem could be due to time since lot 941 is closing in on 
its expiration date. Unfortunately, since the component was added to the experimental 
model late, the information regarding strip vial precision over time is not available. This 
problem, though, is one of quality control for the producer of the reagent strips. It is an 
aspect of the experiment which must be monitored. Action should be taken if precision 
continues to decreases. Since this effect accounts for most of the variability in the model 
and is not a controllable factor , the overall experiment seems to run well. 
Lastly, the precision testing oflot 564 results in the random effect of vial of strips 
as the largest component of variability. This time, however, the magnitude is 
approximately half that of the measurement error. Since lot 564 is relatively new, this is 
further evidence that vials of reagent strips within the same lot decrease in precision over 
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time as the lot approaches its expiration date. Since lot 564 will be tested again when 
choosing a lot of reagent strips for 12-month follow-up, attention should be paid to the 
variance component estimates, in particular that of strip vial . All other variance estimates 
are negligible. Lot 564 is the chosen lot of reagent strips for the 6 month follow-up field 
experiment, and the tolerance intervals for each pool of sera are used when running quality 
control checks during the 6-month follow-up . 
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IV. MAXIMUM PERCENT ERROR 
One standardized procedure for reporting and monitoring the accuracy of 
cholesterol measurements is the maximum percent error 13' 14. The maximum percent 
error is an easily understandable measure of laboratory precision which incorporates all 
sources of variability in the model. An advantage of this procedure is that maximum 
percent errors from one experimental run to another can be compared, all things being 
equal. 
Since the primary concern in this part of the overall investigation is how well the 
cholesterol reading obtained by the Reflotron reflects the true cholesterol value, the 
variance of a particular cholesterol value is modeled. For a particular pool of sera: 
Yi = LLLYi(;hnnpq )jJKN 
J I: n 
where JKN denotes partially the replication scheme in which J denotes the number of 
rounds of testing, K denotes the number of samples of sera per round, and N denotes the 
number of technicians involved in the testing. 
For the February, 1993 experiments, for a particular pool i=l, 
J K N 
Yi (1kmnq ) = LL.~)~ +Rj(I ) +Sk(lj) + Mm +T,, +&l(;kmnq ) ) 
j =I k=I n= I 
Recall that after the initial precision testing in February, the experiment was modified to 
include the effect strip vial. Hence for the August, 1993 and subsequent experiments, for 
a particular pool i= 1, 
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J K N 
yl (jkmnpq ) = LLLU~ + R j (I) + s k(lj ) +Mm+ Tn + VP + 6i ukmnpq ) ) 
j =I k=I n=I 
The variance components of each random effect can be derived for a particular 
pool j_ Then the maximum percent error can be computed for the average cholesterol 
value for each pool of frozen sera by using the estimated variance components of the 
random effects in the model. Again, the variance component estimation method chosen is 
based on restricted maximum likelihood. 
If we assume that Yi is approximately normally distributed, a measure of accuracy 
termed the maximum percent errorl 3 is given by (for the February, 1993 lot testing): 
and (for the August, 1993 lot testing) : 
where c1,c2 ,c3 ,c4 ,c5 ,c6 are constants dependent on the number oftimes each particular 
factor level is employed in the experiment. They are derived seperately for each 
experiment since the factor levels of each effect in the model are subject to change. P; is 
the overall mean cholesterol value for pool i in the experiment (see Table 4). These Pi are 
also utilized in the adjustment of cholesterol values from worksites to be discussed in 
Chapter VI. This implies that the cholesterol measurement Yi will be within 100* P(a)% 
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of the true value of the sample mean with probability 1 - a 14. This maximum percent 
error can be used to describe the precision of readings already made, and comparisons of 
experiments is possible. From this we can also find the coefficient of variation of Y; as: 
CV(Y;) = P(a)/Za12 
For example, in the August, 1993 precision experiment of Lot 941 , the three 
different pools of sera were measured in two rounds (J=2) with five samples per round 
(K=5) on a randomly assigned machine (M=l 5) by a particular technician (N=3) with a 
reagent strip from a randomly assigned vial of strips (P=5). The variance of each effect 
can be derived. 
J K N J J 
V(LLLR;(I) ) = V(:LI5R;(I))= 225* V(LR1(1) = 225* 2~ = 450~ 
j=I k=I n=I j=I ; =I 
JKN JK JK 
V(LLLSk(IJ)) = V(LL3Sk(IJ) ) = 9* V(LLSk(IJ) ) = 9 *(5* 2)~ = 90~ j=I k=I n=I j=I k=I j=I k=I 
J K N 
V(LLLMm)= V(a1M1 +a.µ 2 + ... +a,,,Mm)=a( a;.1 +a;a; ,+ ... +a!a-;1 =l ~ dM +1;a;,1 +. + 1 ~ a;1 =84a;1 J=I h i n=I 
where a1 +a2+ ... +am = 30 , a,.,= the number of times machine w is utilized in the 
experiment, and m= 1, 2, . . . , 15. 
J K N N N 
V(LLLTJ= V(L5* 2Tn) = lOO*V(LTJ = 100 * 3a; = 3ooa; 
J=I k=I n=I n=I n=I 
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J J: N / - 2_:;. b 2' b 2 -2_ 2 -2 2-2 +62 -2_36*5 ' -}80-2 V(LLLVr) = V(br1 + bF 2 + .. +bri r) - b1 '-'v + 2 o;:. + ... + rav - 6 av + 6 av +.. . av - ~ - av 
1=t ,t=I n=l 
where bz = 6 =the number of times vial of reagent strips z is utilized in the experiment and 
p=l , 2, . . . , 5. 
J K N 
V(LL~:C·i;kmnpq) = 30a; 
j =I k=I n=I 
Thus, this implies that the variance of Y; is given by: 
which in turn gives the following equation for the maximum percent error: 
P ( ) - [ dR ds 7 d,.1 ~ o?, a; ]112 /p a -Z - + - +--+- +-+- . 
a/ Z 2 10 75 3 5 30 I 
After choosing the level of significance, the maximum percent error can be computed for a 
particular level of the pool effect . For example, the maximum percent error of the HJGH 
pool in the August, 1993 lot testing is: 
P(.05) =I. 96[ _2. + _Q_ + 7(2. 00268) + _2. + 40. 61229 + 13. 93 725]112/226. 04042 = 0.0257 oc. 2.57% 
2 10 75 3 5 30 
With 95% probability, the summary measurement for a pool will be within 2.57% of the 
true value. Note that the variance contribution due to vial of strips is large in comparison 
with all of the other random effects. And the coefficient of variation is: 
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CV= P( . 05)/za/~ = 0.0257/1 .96=0.0131 oc 1.31% 
Similarly, for all levels of the pool effect and each experiment run, the variance 
components of each random effect can be derived, the maximum percent error calculated, 
and the coefficient of variation computed. For the maximum percent errors and 
coefficients of variation for each experiment run, refer to Table 5. For each experiment 
run, the maximum percent error for each pool of sera is small (less than 4%). The results 
from the testing were well within the allowable ranges for coefficient of variation ( cv<5%) 
set by the NCEP. When comparing the August, 1993 experiments, it is noteworthy to 
mention that Jot 564 has maximum percent errors about half those of lot 941 . This is 
ultimately due to the magnitude of the strip vial effect. 
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V. CONFIDENCE INTERVALS ON VARIANCE COMPONENTS 
Thus far, point estimates of the variance components in the experimental model 
have been computed and analyzed. Point estimation entails selection of an estimate based 
upon a sample which "best" represents the parameter of interest. "Best" means that in 
some sense the estimate is close to the value of the unknown parameter 15. Sometimes 
this point estimate is close to the target value and sometimes it is not close depending on 
the sample utilized for estimation. This is because the sample values are values of random 
variables. Sometimes a "good" sample is taken, one that exemplifies the population of 
interest, and sometimes a "bad" sample is taken. Hence, sampling error is to be 
anticipated. Not only is a point estimate necessary, but information as to the accuracy of 
the estimate is needed. This is accomplished by utilizing confidence intervals. 
Burdick & Graybill consider interval estimation to be more informative than point 
estimation because in most studies, it is generally not enough to obtain a single value for 
the parameter under investigation. And, it is usually preferable to have some confidence 
that specified limits (upper and lower bounds) include the unknown value of the 
parameter. Also, confidence intervals can be used to test hypotheses. They argue that 
"confidence intervals are the most informative summary results of statistical inference and 
should be used whenever possible" 15 . · 
When dealing with the experimental model, not only does the interest lie in 
determining the magnitude of each variance component in the model, but also in the 
magnitude of the overall variance of the response variable. So, utilizing methods of 
constructing confidence intervals from Burdick & Graybill, confidence intervals were 
computed for each variance component in the model (a; , ifs , du , d;. , Of, , d!) and for the 
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total variance of the response variable ( 8 = var(Yvkmnpq )). The general procedure for 
computation is as follows . 
Each expected mean square is a linear function of the variance components. 
Setting confidence intervals on these variance components is accomplished by setting 
confidence intervals on linear combinations of the expected mean squares. Exact and 
approximate confidence intervals have been developed. When computing confidence 
intervals on each variance component, the representative model was the unbalanced two-
fold nested random model. (See Table 7 for analysis of variance model). When the sums 
of squares are not independently distributed chi-squared which happens to be most of the 
time (all effects except the error) with this type of design, the calculations required to 
compute the confidence intervals become lengthy and involved. Unweighted sums of 
squares are utilized in constructing confidence intervals and, although the assumption that 
the mean squares are independent chi-square random variables is not generally met, this 
approach has worked well 15 . The resulting confidence intervals generally perform well 
and maintain the stated level of confidence. 
A. Point Estimates of Individual Variance Components 
A point estimate for each random effect is computed using the unweighted mean 
squares (MS) and expected mean squares (EMS) found in the analysis of variance table 
pertaining to this experimental design (Table 7). The resulting ANOVA tables for each 
precision experiment run were generated utilizing SAS proc glm (Table 8)11. These point 
estimates of each variance component are: 
Round · ~ = ({}, -(w 3u) * (). + (w 3u -1) * B >)w 
· R lu 2u 6 4u 
w 5u w 5u 
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Error: d! = 86 
where equ is the expected mean square of the q th variance component ( q= 1, ... , Q) which is 
estimated by s:u, the mean square of the qth variance component. The formula for aj is 
found by algebraically manipulating the equations for the EMS and solving for the jth 
random effect. Any negative point estimate is defined to be zero. 
B. Construction of Confidence Intervals on Individual Variance Components 
Computation begins with the first random effect in the experimental model. Since 
the first random effect (round) has a second random effect (sample) nested within it, the 
formula for the computation of a confidence interval is somewhat more involved than the 
rest. Hernandez et al 16 recommended using unweighted mean squares when constructing 
this confidence interval. This approximate two-sided 1- 2a confidence interval on a; is 
given by: 
31 
where 
w 
C ---1.!L 2 -
w 5u 
G1 = 1 - 1/f~. n, ,or:i for l = l,2,6 
H 1 = 1/ F"i-a,n,."' - 1 for I = 1, 2, 6 
and 
for I= 2,6 
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for l = 2,6 
and S1~ ,S~u , S~ are the Type Ill unweighted mean sum of squares generated by SAS 
(Tables 7 and 8). 
For confidence intervals on the other random effects in the experimental model, the 
calculations are less cumbersome since no factor in the model has another factor nested 
within it. Again, these are only approximate confidence intervals. For random effect k, an 
approximate 1- 2a confidence interval on a; can be constructed as follows: 
w (k +3)u 
where 
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H 2s-+ G2S4 H c<! s 2 Vu = k ku + 6 6 + k6 .J tu 6 
G1 =1-1/Fa,n,.oo for / = 2,3,4,5,6 
H 1 =1/F..-a.n,,oo - 1 for /=2,3,4,5,6 
Lastly, the exact two-sided 1- 2a confidence interval on 06 = a; is : 
The resulting 95% confidence intervals on the variance components within each 
run of the precision testing experiment are located in Table 9. Any negative bounds are 
defined to be zero. 
C. Point Estimate of Total Variability 
Now, attention turns to the overall variability of the model. A point estimate of 
the total variance of the response variable denoted 8 is obtained as follows. The 
experimental model contains Q=6 sources of variation in the model . The variance of the 
experimental model is the sum of all the variable effects in the model. 
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8= ~+~+~+a';.+ dv + ~ = var(YiJkmnpq) 
Since 8 is a linear combination of EMS, some EMS may have different signs. Let P 
represent the number of EMS with a positive sign. In each experiment in this study, Q=P 
(See Tables 7 and 8). The estimates of ()qu may be negative but the expected value of ()qu 
is positive. This simplifies calculations concerning 8 . By replacing each ~ with the 
appropriate linear combination of EMS, the above equation becomes: 
After some algebraic manipulation, the point estimate formula is given by 17: 
In estimating 8, the unweighted mean squares are used to estimate the expected mean 
squares. Hence, s:u is used in place of ()qu . 
~ . p Q 
8= L_cqs: - L_crs; 
q= I r= P+ I 
Since the linear combination of interest contains all positive EMS, Q=P, the equation for 
6 simplifies to: 
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where 
C2 = lfw5u -w3j(w 4u W5.,) 
C3=ljw6u 
C4 = lfw1u 
C5 = lfw su 
c6 =w 3u /(w4uw s.J-1fw2,, -1/w3,, -1jw4u -1/wsu -ljw6u +I 
D. Construction of Confidence Limits on Total Variability 
Ting et al I 7 developed the following interval for 8 with Q>2. The lower bound 
on an upper I - a confidence interval on 8 is: [ L, oo ) 
where 
P Q P Q P - 1 P 
VL = L,c:c~s; + L. H;c;s: + L. L,Gqrcqcrs:s; + L,L,c;1cqc1s:s12 
q=l r =P +l q=l r=P+l q=l t>q 
Since Q=P, this equation simplifies to: 
P P - 1 P 
VL = L,c:c:s; + L,L,c;1cqc1s:s12 
q=l q=l t>q 
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where 
G = 1-11 Fa.n 00 for q = 1, ... ,P q '/ q • 
(n + n )2 G 2 n G 2 ) G·,=((1-1 1Fa.n+n oo )2 * q t _ __!l_!f_ _~) (P-1) 
q '/ · 9 ' ' n n n 11 
. q t t q 
(t=q+l, ... ,P) 
The upper bound on a lower 1- a confidence interval on 8 is: [O,l! ] 
where, 
p Q p Q Q - 1 Q 
Vu = L.H:c:s; + L G;c;s: + L L.Hq,cqc,s:s; + L L.H:c,c,.s;s~ 
q=I r=P+I q=I r=P+I r= P+I u>r 
Since Q=P, this equation simplifies to: 
p 
Vu = "LH:c:s; 
q=I 
where 
H, =l/F..-a,n,,oo -1 for /=1,2, 3,4,5,6 
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for results of point estimation and confidence limits, refer to Table 9. The random 
effects for technician and measurement error prove to have the largest magnitude relative 
to the other variance components in half of the experiments, all performed in February. In 
turn, ifr has the widest confidence intervals. Also, the round of experimentation is a 
modest fraction of the variability in the model. In the August experiments, the lot testing 
of941 results in the newly added strip vial effect being 2.5 times the magnitude of the 
measurement error which greatly inflates the confidence range. Again, it is important to 
note that the technician component is not significant, suggesting possible confounding 
between strip vial and technician in the earlier experiments. The machine and strip vial 
effects have the widest intervals in the lot testing of 564. However, the lower bounds on 
the individual confidence intervals are almost and less than zero, respectively. 
ln summary, the experimental design utilized in this study can perfom1 well wi th 
reasonably minimal variability if protocol is followed . Since the strip vial effect is so great 
in August testing oflot 941 but not unreasonable large in lot 564, perhaps the effect is 
dependent on time. It seems reasonable to suggest that the older the lot of reagent strips, 
perhaps the greater the variability in vials of reagent strips within the lot. 
We expect confindence intervals on variance components to be skewed, since they 
are based on the F -distribution which is not symmetric. However, the individual point 
estimates appear to be much closer to the lower bounds of the 95% confidence intervals 
with some upper bounds being unreasonably large. This happens when the magnitude of 
the mean square of the variance component in question is large in comparison to the 
measurement error. Also, the fewer the degrees of freedom associated with the variance 
component in question, the larger the constants utilized in calculating these upper bounds. 
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Jn the February experiments, recall that the technician error is significant in 3 of 
the 4 experiments run . This suggests that protocol was not followed properly, and/or 
there is another source of variation not yet identified that attributes to this technician 
component, and hence resulting in the large upper bound for it. In the August 
experiments, the strip vial component proves to be the most variable. The technician 
variation in these experiments is negligible. Perhaps the technicians are more experienced 
with the cholesterol measurement process. Or, this new source of variation was 
confounding the technician variability. From these August experiments, it is clear that 
vial-to-vial variation within a lot of reagent strips is significant. However, when 
comparing the two experiments run, something else is evident. The new lot 564 has a 
strip vial estimate of reasonable size. Lot 941 does not. The resulting confidence interval 
is large. This may be partially attributed to the fact that lot 564 is close to its 
manufacturing date while lot 941 is approaching its expiration date. As the lot of reagent 
strips ages, the variability between vials of strips increases. Since no experiments were run 
between February and August, it is not known how quickly or at what rate the lots of 
reagent strips deteriorate. 
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VI. THE FIELD EXPERIMENT 
The final stage of this research centers around cholesterol screening at worksites in 
the study. Cholesterol measurement at a particular worksite takes a few days to complete. 
The types of worksites recruited for this study are primarily manufacturing and 
distribution companies with 250 to 800 employees that employ at least one full-time 
occupational nurse. All worksites chosen are within sixty miles of Memorial Hospital in 
Pawtucket, Rhode Island. 
So, now that a worksite is recruited, volunteers must be recruited to participate in 
the study. It has been found that a free cholesterol screening is very motivating. The 
volunteers participating in this experiment are required to meet certain criteria. They must 
be able to understand and sign an informed consent form. They must be at least 20 years 
old and not pregnant. They must not have suffered a stroke, heart attack, or surgery in 
the previous 2 months. They must be able to read and speak English. Lastly, they must 
plan to be employed at the worksite for the next year, making them eligible for follow-up 
study. 
Since the 6 month follow-up occurs at a different time of year than the baseline, 
the possible seasonal variation of cholesterol values was of concern. Total cholesterol 
levels have been documented as lower during the summer and higher during the winter, 
presumedly reflecting changes in dietary intake, physical activity, body weight, and other 
factors. This lead to the selection of September, October, November, and March, April, 
May as the two blocks of time that were ideal for baseline, 6-month and 12-month follow-
ups. 
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Individuals meeting the afore mentioned criteria first fill out a participant 
registration form. Then the technician running the experiment takes a blood specimen 
from the individual and obtains a cholesterol value for him/her utilizing the fingerstick 
method. Depending on the experimental condition the worksite belongs to, appropriate 
action is taken regarding the individual's cholesterol level (Appendix A, Figure 1 ). The 
specific machine and the specific technician utilized are recorded. Since the participants 
are assigned randomly, it is possible to monitor the cholesterol values being produced by 
any specific technician or machine, identify measurement problems not found by the daily 
quality control procedures and take remedial action. 
The proposed daily quality control protocol to be employed in the field is the 
following. At the beginning and end of every day that a Reflotron machine is used the 
technician must : 
1. Test the first sample of sera (HIGH or LOW) 
2. If the first sample falls within the 95% tolerance range (for the specific lot of 
reagent strips being used), document the value and proceed with the scheduled screenings. 
3. If the first sample is outside of the 95% tolerance range, test another sera 
sample (from the same pool) . 
4. If the second sample is outside of the range IN THE SAME DIRECTION, 
reject the machine. Begin procedure again with another Reflotron desktop analyzer. The 
rejected machine is eliminated from further use until it has been repaired. 
Using this protocol, it is expected that a machine would be falsely rejected 1 out of 800 
times. The overall Type I error rate was calculated as 0.025*0.025*2=0.00125 . This type 
of quality control check is suggested to be made periodically throughout the day while 
cholesterol testing is in progress (after every 20th measurement). This process of QC 
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measurement has been documented in some other cholesterol screening 
experiments 18, 19,20_ Hopefully, a malfunctioning machine is found before too many 
observations are taken. These Reflotron obtained cholesterol measurements must be 
adjusted since it has been shown previously that each specific lot of reagent strips 
underestimates the individual's true cholesterol value to some degree. Thus, for each day 
of testing at a worksite with a particular machine utilizing a specific lot of reagent strips, 
median high and low sera cholesterol values are computed for the calibration of individual 
cholesterol measurements. For the Baseline measurements, lot 941 was the lot of reagent 
strips utilized. It fared well in both the initial lot testing and the precision testing, and, 
hence, became the lot of choice. 
The data resulting from this worksite screening consists of the following variables 
of interest : 
1. FORM NUMBER - an individual's _identifying number. 
2. REFLOTRON MACHINE IDENTIFIER - number used to identify the 
machine used. 
3. LOCATION CODE - identifies the worksite the individual belongs to . 
4. DATE OF TEST 
5. TECHNICIAN CODE - initials of technician who performed the test. 
6. LOW SERA VALUE - quality control check value. 
7. HIGH SERA VALUE - quality control check value. 
8. COMMENTS - any comments the technician took note of 
A. The Two-Step Adjustment 
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The Reflotron obtained cholesterol value given to an individual participant is 
representative of his/her true cholesterol value. These Reflotron obtained cholesterol 
values must be adjusted or calibrated to reflect the actual or true cholesterol value. This 
is sometimes termed inverse estimation. The object is to transform the fingerstick value to 
a gold standard value. This results in values used to test hypotheses concerning total 
blood cholesterol on a worksite-wide basis. The two-step adjustment procedure discussed 
in this section is suggested by the research staff associated with this project at the 
Memorial Hospital . 
The first step in the adjustment of cholesterol measurements is to make a daily 
calibration as follows. For each individual cholesterol measurement taken, certain 
information is recorded about the machine and technician involved. For this particular 
machine and technjcian on a specific day are recorded quality control check values. The 
median values for the high and low sera QC checks (Pm,) are calculated. Now, these 
mediim values are linked to the overall mean cholesterol values for pool high and pool low 
(P,) in the precision lot testing for the particular lot of reagent strips used. Regressing the 
daily median high and low QC checks on the overall high and low mean cholesterol values 
gives the following equation: 
·Z-a +aY 
- 0 I 
where Z is the observed cholesterol value measured on a particular day at a specified 
worksite, and Y is the observed cholesterol measurement adjusted for time. Let z0 be the 
observed of Z . A point estimate of the corresponding value of Y is given by 7: 
43 
Now, an adjustment must be made to transform a Reflotron obtained cholesterol 
value into a true cholesterol value. The relationship between fingerstick obtained 
cholesterol values measured by a specific lot of reagent strips and gold standard values 
was determined in Chapter II - Accuracy Testing as: 
where Y is the Reflotron obtained cholesterol measurement adjusted for time, and X is 
the true cholesterol value. Since y 0 is the observed value of Y , a point estimate of the 
corresponding value of X is given by: 
This approach is often called the classical estimator. x
0 
is a biased estimator of x0 which 
has an infinite mean square 7. 
The following example illustrates this two-step adjustment procedure. Suppose 
"Joe Smith" had his cholesterol level measured at his worksite on March 17. 1993 . The 
technician in charge used Reflotron machine "C" with a reagent strip from lot 941 . The 
resulting fingerstick value obtained is 230mg/dl. This is not Joe Smith's true cholesterol 
value. 
It is necessary to make a daily calibration of cholesterol values. To do this, one 
must first obtain the median quality control sera values per pool for the particular day of 
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testing on the specified Reflotron machine. The following are the quality control checks 
made on March 17, 1993 and the median values for the high and low sera quality control 
checks .. 
Low Sera 148 
Hig_h Sera 240 
174 
234 
Pm/ = 156.5 
Pmh = 235 
157 156 
235 
Notice that there is one more low sera check than high sera check. This is because the 
low sera check value of 174mg/dl fell outside of the 95% tolerance interval for the low 
pool. The technician was following protocol by checking another low sera sample to 
determine if the machine should be rejected. However, the next sera sample resulted in a 
cholesterol value within the specified range so testing continued with machine "C". 
Next, Z (Pmz and Pmh) are regressed on Y (P1 and Ph), the overall mean 
cholesterol values per pool from the precision testing (Table 3). 
The resulting equation is: 
pl = 157.28 
Ph = 239.75 
Z = 6.791257 +0.951861Y 
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and Joe Smith's Reflotron obtained cholesterol value z0 =230 after adjustment for day-to-
day variation is: 
= zo - a o = 230-6.791257 = 234.50 
Yo a1 0.951861 
The second step of the adjustment procedure will transform Joe Smith's adjusted 
Reflotron obtained cholesterol value to a gold standard value. It is known from the initial 
lot testing of lot 941 that the Reflotron value (Y) is related to the true cholesterol value 
(X) by the following regression equation (Table 2). 
Y = 5.624063+0.936384X 
Taking y 0 =234 .50, Joe Smith's estimated true cholesterol value is: 
x =Yo::- /30 = 234.50-5.624063 = 244.43 0 /31 0.936384 
Hence, Joe smith obtained a cholesterol value of230mg/dl from the worksite screening 
which places him in the moderate risk category. However, his estimated true cholesterol 
level is more than 14mg/dl higher. Joe Smith actually falls into the high cholesterol risk 
category. Since the study focus is not on the individual participant, this estimate is 
acceptable. Unfortunately, at the time of experiment, Joe Smith is given only his 
fingerstick cholesterol value which minimized his risk. 
B. Prediction Interval on Point Estimate 
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It has been discussed previously that point estimates may not contain enough 
information. The accuracy of the estimate is needed. This can be accomplished by 
computing prediction intervals for the point estimate. In this case, calibration intervals are 
appropriate. Montgomery and Peck 7 recommend testing the hypothesis 
Ho: A =0 
If this hypothesis is not rejected, then no linear relationship exists between y and x 
rendering a point estimate or a confidence interval meaningless. The width of the 
prediction interval on x0 depends on how greatly Ho: {J1 = 0 is rejected. A short interval 
is obtainable if the hypothesis is rejected with a large F -statistic. And, a wide interval will 
result from a small F-statistic. However, this hypothesis was rejected for lot 941 (Table 
2) . The 100(1 - a)% prediction interval for x
0 
is7,21: 
where d1 and d 2 are the roots of 
After some algebraic manipulation, the roots of the above equation are found to be22,23 : 
_I_[( - -) + t~12 .>J-2 (y2 
I 2 Yo Y - A - c p I 
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This gives an individual observation fonnula, applicable to a single new cholesterol 
measurement. If we replace (1 + _!_) with ( _!_ + _!_) , where q is the number of observations 
n q n 
x is based on, the calculations are now based on true mean value calculations which 
0 
enables the generalization to the multiple predictor case. 21 
To continue with the Joe Smith example, it is desirable to place a 95% prediction 
interval on x0 =244.43 , his estimated true cholesterol value corresponding to an adjusted 
Reflotron obtained cholesterol measurement of 234.50. This gives a range of values to be 
concerned with. For the data involved (Appendix B, Figure 1 ), S = = 39268.63, S y:.·= 
35898.10, S xy = 36770.53 . Recall that p1 = 0.936384 and p0= 5.624063 . It follows that 
SSE = 1466. 77. The estimate of a 2 = 86.280319 is based on (n - 2) = 17 degrees of 
freedom. For a =.05, t a/i.17 = 2.093 . 
c2 = (2.093)2 (86.28) =.OllO 
(. 936384)2 (39268.63) 
and 1- c2=.9890. Using x0 = 244.43 , the upper and lower prediction limits for x when 
y=234.50 are as follows: 
(x x ) = 202. 58 +-1-[41.85 ± 2.093(9.29) (20)(. 9890) + (41.85)2 ] 
L> U .9890 0.9363841 19 39268.63 
(XL,XU) = (223.0,266.8) 
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Joe Smith should be concerned with his cholesterol level. The prediction interval 
for Joe Smith's estimated true cholesterol value has a range spanning the moderate and 
high risk category. Since there is a very strong linear relationship between Reflotron 
obtained and gold standard values, the prediction interval is small and contains information 
a point estimate does not. 
C. Recommendations for Next Time 
The two-step adjustment procedure previously explained is the adjustment chosen 
to be utilized with the field experiment data. It is based on the quality control sera checks 
taken daily at a worksite. The protocol requires these sera checks to be run every 20 
observations. However, this is not the case. No information is available as to the order of 
participant testing and the order in which the sera checks were made between participants. 
If these data were available, it would be easier to determine when a machine malfunctions. 
Depending on when the change took place, different adjustments could be made for 
cholesterol values of participants tested. But, how is it easier to determine when the 
process went astray? Prior information concerning participants' cholesterol levels must be 
known. Participants responded to the Cholesterol Change at Work survey which includes 
questions of past cholesterol testing . ·In particular, the following questions would give the 
prior information necessary to more readily detect the change point. 
How long has it been since you last had your cholesterol measured? 
1. Never had it measured 
2. Less than 6 months 
3. Between 6 months and I year 
4. More than 1 year 
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What was your blood cholesterol level the last time you had it measured? 
1. (number) 
2. I was not told 
3. Don't remember 
4. Never had it measured 
If an individual had his/her cholesterol measured within the last 6 months and 
recorded the actual number, then a comparison of the prior and current cholesterol values 
of this participant could be made to determine if the malfunction occurred before or after 
this person's cholesterol measurement in the field . Since the prior information includes a 
cholesterol value within the last 6 months, the current cholesterol value should be within a 
range of seasonal variability, other things being equal. 
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Vil. SUMMARY 
The results of the reliability testing are fair . The initial lot testing determined that 
the overall accuracy of the reagent strip lots is not within the NCEP guidelines 
(bias<=5%). The Reflotron obtained cholesterol measurements are negatively biased, 
consistently underestimating the true cholesterol values. However, both lots 941 and 942 
in February, I 993 and lot 564 in August, I 993 warranted further testing. The precision 
testing resulted in the determination of the lot of reagent strips to be used in the field 
experiment. The coefficients of variation resulting from the precision experiment are well 
within the allowable range (<=5%). And, the maximum percent errors are small for each 
experiment conducted (P( .05)<=4%). In the August experiments, lot 564 has maximum 
percent errors approximately half those of lot 941 . Again, this may possibly be attributed 
to the expiration date of lot 94 I approaching. Lot 94 I was the reagent strip selected for 
the baseline field experiment and lot 564 selected for the 6-month follow-up . 
Confidence intervals on the individual variance components and the total variability 
in the experimental model give an estimated range of possible variability. The major 
component to the variability of the model appears to be the technician-to-technician 
variability in the February experiments and the vial-to-vial variation in reagent strips in the 
August experiments. 
The field experiment yields cholesterol measurements on participants at worksites. 
These values are underestimates of the true cholesterol levels of the participants. The 
two-step adjustment procedure utilizes the results of the accuracy and precision 
experiments to determine the estimated true cholesterol values. These predicted values 
are to be utilized in the analysis of the field experiment. The construction of prediction 
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intervals on individual predicted cholesterol estimates help minimize the misclassification 
of individuals into the cholesterol risk categories. 
The reasons for wide-spread cholesterol testing are well documented. And 
cholesterol testing·with the Reflotron machine has many advantages over other cholesterol 
measurement methods. The most important advantage is the portability of the Reflotron 
machine which allows the movement of the desk-top analyzer to where people are. This 
frees the process from usual laboratory space requirements. This characteristic increases 
participation rates and decreases expenses. 
Recently, medical waste disposal in the environment has been highly publicized and 
regulations regarding disposal have become increasingly restrictive. The Reflotron 
minimizes the amount of medical waste resulting from cholesterol screening since the 
process involves minimal supplies and no needles, unlike method involving veneous blood 
samples. This dry-chemistry method is also much less expensive to use than wet-
chernistry methods. The materia~s needed for Reflotron use are mostly plastic and are 
mass produced. And, the Reflotron is simple to use. Thus, operators need minimal 
training to achieve reliable results. 
However, things can go wrong. Accuracy in the field is dependent on some 
important factors . Adequate cleaning of the Reflotron machine is critical to the accuracy 
of the test . Protocol must be followed to maintain reliable results. Deviations from 
protocol can reduce the accuracy, as can distractions in the testing area. Even subjecting 
the Reflotron machine and materials to excessive temperature changes can reduce the 
accuracy. 
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At half of the worksites, those belonging to the external condition (Appendix A, 
Figure I), project staff are employed. The Reflotron machines utilized by them are 
transported daily to and from the worksite in a project staff vehicle. This constant 
transportation is sure to affect the performance of the Reflotrons. 
Continuous data monitoring of the machines and a strict data reporting and 
analyzing protocol are necessary. However, there tends to be a built-in disincentive to 
report extreme values resulting from quality control sera checks. If a technician continues 
to employ a malfunctioning machine either unintentionally or intentionally, accuracy of the 
test would be affected. The ideal situation would be to have some sort of device on the 
Reflotrons involved in the study which automatically records the quality control values. 
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VI 
°' 
February, 1993 
Lot 941 
Lot 942 
August, 1993 
Lot 941 
Lot 943 
August, 1993 
Lot 941 
Lot 564 
Table 1 
Initial Lot Testing Results 
Percent of Observations Within the NCEP Guidelines 
% observations % observations Average Percent 
within within Change from Gold Standard Deviation 
± 14.2% ± 8.9% J..% Bias_l 
100.0 84.2 -3 .6 0.043 
100.0 78.9 -5 .1 0.047 
75.8 60.6 -8.0 0.057 
72.7 27.3 -11.4 0.041 
73.3 43 .3 -10.2 0.059 
100.0 70.0 -6.5 0.043 
VI 
-..J 
Lot 941 (2/93) 
Po 
P1 
Lot 942 (2/93) 
Po 
Pi 
Table 2 
Initial Lot Testing Results 
Simple Linear Regression Parameter Estimates 
Parameter Estimate Standard Error 
5.624063 9.732 
0.936384 0.047 
-26.386923 9.777 
1.085048 0.047 
Prob> I Tl 
H . ro"O 0 . "'""' ,,,., 
0.5709 
0.0001 
0.1925 
0.0152 
0.0001 
0.0887 
Vi 
00 
Lot 941 (8/93) 
Po 
p, 
Lot 943 (8/93) 
Po 
p, 
Lot 941 (8/93) 
Po 
p, 
Lot 564 (8/93) 
Po 
p, 
Table 2 (con't) 
Initial Lot Testing Results 
Simple Linear Regression Parameter Estimates 
Parameter Estimate Standard Error 
-29.047838 8.797 
1.065342 0.041 
-8.230145 6.990 
0.927026 0.033 
-68.184786 9.003 
1.224978 0.042 
-32.148122 10.064 
1.088572 0.047 
Prob>ITI 
("o=O Ho: ,,,=o 
,,,., 
0.0025 
0.0001 
0.1234 
0.2483 
0.0001 
0.0335 
0.0001 
0.0001 
0.0001 
0.0034 
0.0001 
0.0697 
Vl 
'° 
Pool 
High 
Med 
Low 
Mean 
Cholesterol 
-
Value= I>; 
239.75 
214.86 
157.28 
Standard 
Error 
1.09 
1.13 
1.06 
Table 3a 
P; and Factor Levels & Values 
February, 1993 Lot Testing 
1st 941 
Factor Levels 
Pool 3 High, Med, Low 
Round 2 1 2 
Sample 6 123456 
Values 
Machine 19 123 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Technician 3 ] 2 3 
Number of Observations in Data Set = 108 
°' 0 Pool 
High 
Med 
Low 
Mean 
Cholesterol Standard 
- Error Value= I'; 
236.87 0.77 
214.74 0.84 
152.01 0.87 
Table Jb 
P; and Factor Levels & Values 
February, 1993 Lot Testing 
2nd 941 
Factor Levels 
Pool 3 High Med Low 
Round 2 34 
Sample 6 123456 
Values 
Machine 18 3 4 5 6 7 8 9 IO 11 I 2 I 4 15 16 17 18 19 20 21 
Technician 3 l 2 3 
Number of Observations in Data Set = 108 
Mean 
°' Pool Cholesterol Standard 
Value=P; Error 
High 242.75 0.70 
Med 220.15 0.77 
Low 152.22 0.79 
Table Jc 
P; and Factor Levels & Values 
February, 1993 Lot Testing 
1st 942 
Factor Levels 
Pool 3 High Med Low 
Round 2 I 2 
Sample 6 123456 
Values 
Machine 18 123456789101112131415161718 
Technician 3 1 2 3 
Number of Observations in Data Set = l 08 
°' N Pool 
High 
Med 
Low 
Mean 
Cholesterol Standard 
- Error Value= P; 
249.39 0.85 
224.36 0.93 
152.59 0.96 
Table 3d 
P; and Factor Levels & Values 
February, 1993 Lot Testing 
2nd 942 
Factor Levels 
Pool 3 High Med Low 
Round 2 l 2 
Sample 6 I 23456 
Values 
Machine 18 123456789101112131415161718 
Technician 3 1 2 3 
Number of Observations in Data Set = 108 
°' w 
Pool 
High 
Med 
Low 
Mean 
Cholesterol Standard 
- Error Value=?; 
226.04 0.80 
207.69 0.76 
148.57 0 .82 
Table 3e 
P; and Factor Levels & Values 
August, 1993 Lot 941Testing 
Factor Levels 
Pool 3 High Med Low 
Round 2 I 2 
Sample 5 l 2 3 4 5 
Values 
Machine 15 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Technician 3 1 2 3 
Strip Vial 5 12345 
Number of Observations in Data Set = 90 
Mean 
Pool Cholesterol Standard 
~ - Error Value=P; 
High 231.17 0.83 
Med 212.85 0.79 
Low 154.78 0.85 
Table Jf 
P; and Factor Levels & Values 
August, 1993 Lot 564 Testing 
Factor Levels 
Pool 3 High Med Low 
Round 2 1 2 
Sample 5 123 4 5 
Values 
Machine 15 123456 7 8 9 10 11 12 13 14 15 
Technician 3 I 2 3 
Strip Vial 5 1 2 3 4 5 
Number of Observations in Data Set = 90 
°' Vl 
Variance 
Component 
Jst 941 
Round 
Sample 
Machine 
Technician 
Error 
2nd 941 
Round 
Sample 
Machine 
Technician 
Error 
Table 4 
Estimation of Variance Components 
by Different Methods 
February, 1993 Lot Testing 
Method of Estimation 
TYPE I MIVQUE(O) ML 
7.9122 7.9500 2.9986 
-2.7953 -3 .0684 0 
1.0055 4.3376 3.5110 
9.6260 9.2385 6.6468 
28 .9153 26.2792 24.5482 
3.4425 3.4569 1.2187 
-0.7038 -0.6940 0 
-0.5464 0.2971 0.2877 
0.1926 0.2158 0.0884 
19.7965 18.9611 18.4013 
REML 
6.3869 
0 
3.3500 
9.5015 
24.6336 
3.3807 
0 
0.4213 
0.2366 
18.2133 
°' 
°' 
Variance 
Component 
Jst 942 
Round 
Sample 
Machine 
Technician 
Error 
2nd942 
Round 
Sample 
Machine 
Technician 
Error 
Table 4 (con't) 
Estimation of Variance Components 
by Different Methods 
February, 1993 Lot Testing 
Method of Estimation 
TYPE I MIVQUE(O) ML 
0.6844 0.6962 0 
2.7320 2.7401 2.4425 
I .2903 1.9823 1.9747 
6.5440 6.5630 4.3853 
16.4820 I 5. 7967 I 5.9289 
0.3794 0.4222 0 
-0.5667 -0.5376 0 
0.2294 2.7324 2.5123 
3.0944 3.1633 2.0453 
24.1847 21. 7055 21.0923 
REML 
0.7229 
2.5252 
2.0440 
6.5599 
I 5.9093 
0.2041 
0 
2.6170 
3.1721 
21.3880 
°' -....J 
Variance 
Component 
941 
Round 
Sample 
Machine 
Technician 
Strip Vial 
Error 
564 
Round 
Sample 
Machine 
Technician 
Strip Vial 
Error 
Table 4 (con't) 
Estimation of Variance Components 
by Different Methods 
August, 1993 Lot Testing 
Method of Estimation 
TYPE I MIVQUE(O) ML 
-0.1289 0. 1082 0 
-0.3428 -0.5242 0 
3.8312 4.7897 1.9901 
-0.0706 0.0447 0 
38.1914 41.2412 32.4448 
15.0513 11.5927 13 .5874 
-0.9731 -0.8002 0 
3.7710 3.3566 0 
4.7540 1.1428 2.6175 
0.3138 0.3026 . 0.2235 
4.0225 8.0873 7.3342 
16.4201 16. 7556 17.4344 
REML 
0 
0 
2.0027 
0 
40.6123 
13 .9373 
0 
0 
2.7609 
0.2673 
9.1771 
17.8136 
°' 00 
LOT 
941 
942 
Table 5 
95% Tolerance Limits for Pool i of Sera 
February, 1993 Lot Testing 
P; ± Z0025 ~CT~ +CT~ +CT~ +CT~ +CT; 
POOL LB 
High 227 
Medium 202 
Low 145 
High 238 
Medium 213 
Low 141 
LB = Lower Bound 
UB = Upper Bound 
UB 
252 
227 
170 
260 
235 
164 
°' \0 
LOT 
941 
564 
Table 5 (con't) 
95% Tolerance Limits for Pool i of Sera 
August, 1993 Lot Testing 
; - 002s .an +as +a M +a r +a v +a,. p + z ~ 2 2 2 2 2 2 
POOL LB 
High 211 
Medium 192 
Low 133 
High 220 
Medium 202 
Low 144 
LB = Lower Bound 
UB = Upper Bound 
UB 
241 
223 
164 
242 
224 
166 
-...I 
0 
Table 6 
Maximum Percent Error & Coefficient of Variation 
August, 1993 Lot Testing 
.>-; will be within 100 * P( a)% of the true value of the sample µ P, 
with 1 - a probability 
Ex_p_eriment Maximum Percent Error Coefficient of Variation 
a =.05 
1st 941 
High 2.21% 1.13% 
Medium 2.47% 1.26% 
Low 3.37% 1.72% 
2nd 941 
High 1.26% 0.64% 
Medium 1.39% 0.71% 
Low 1.96% 1.00% 
1st 942 
High 1.47% 0.75% 
Medium 1.63% 0.83% 
Low 2.36% 1.20% 
2nd 942 
High 1.09% 0.56% 
Medium 1.22% 0.62% 
Low 1.80% 0.92% 
-..J 
-
Table 6 (con't) 
Maximum Percent Error & Coefficient of Variation 
August, 1993 Lot Testing 
Y; will be within IOO* P(a)% of the true value of the sample µ P, 
with 1 - a probability 
E~eriment Maximum Percent Error Coefficient of Variation 
941 
High 
Medium 
Low 
564 
High 
Medium 
Low 
a =.05 
2.57% 
2.79% 
3.91% 
1.41% 
1.53% 
2.11% 
1.31% 
1.43% 
1.99% 
0.72% 
0.78% 
1.08% 
-....J 
N 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Strip Vial 
Error 
Total 
Table 7 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
OF 
no = i-1 
nt = iG-1) 
n1 = ij(k-1) 
n3 = m-1 
n4 = n-1 
n5 = p-1 
"6 =by 
subtraction 
N-1 
SS 
ssou 
SSlU 
SS2U 
SS3U 
SS4U 
SS5U 
SS6 
SST 
MS 
S~u 
sl~I 
Siu 
Siu 
(' 2 
..i4u 
s52U 
s~ 
EMS 
(} 2 2 2 Q ou =aE +w,ua s +ww aR+ P 
(} 2 2 2 IU =a E + WJU (Y S + W4u CY R 
(} 2 2 w =aE+wsu CYs 
(} 2 2 3U = a E + w 6U a M 
(} 2 2 4V = a E +ww ar 
(} 2 2 su = a E + Wsua v 
(}6 =a~ 
-...J 
w 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Error 
Total 
Table Sa 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
February, 1993 
1st LOT 941 
DF SS MS EMS 
2 83204.12 41602.06 (} 2 2 2 Q OU = (J" E + 1.755 lu s + 10.53 lu R + p 
3 233 .74 77.91 (}1u = a-~+ 2.323 lu~ + 13.939u~ 
30 524.05 17.47 (}w = a-~ + 2.4173u~ 
18 618 .94 34.39 (}w = a-~ + 3.6245u~ 
2 738.84 369.42 (} 4u = (J"~ + 3 5J 730"~ 
52 1503.60 28.92 ()5 = (J"~ 
107 131216.77 
-...J 
~ 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Error 
Total 
Table Sb 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
February, 1993 
2nd LOT 941 
DF SS MS EMS 
2 100220.80 50110.40 Bou= a~ +2.2754a; + 13.652a~ +Qp 
3 214.91 71.64 Bw = a~ + 2.5557a; + 15.334a~ 
30 472.00 15.73 Bw =a~ + 2.5029a; 
17 298.66 17.57 (} 2 2 
3U =a E + 4.0784aM 
2 53.46 26.73 (}4u = a~+ 36a~ 
53 1049.22 19.80 (}s = a i 
107 140643.52 
......i 
Vo 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Error 
Total 
Table Sc 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
February, 1993 
1st LOT 942 
DF SS MS EMS 
2 114323.47 571 6 1.74 B0u = CT~ +2 .2754CT~ + 13.652CT~ +Qp 
3 92.98 30.99 (} IU = CT~ + 2.5557CT~ + 15.334CT7i 
30 626.13 20.87 (}2U = CT~ + 2.5029CT~ 
17 369.66 21.74 (}3U = CT~+ 4 .0784CT~ 
2 504.13 252.06 (} 4u = CT~ + 36CT~ 
53 873 .55 16.48 (}5 = CT~ 
107 166119.85 
......i 
°' 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Error · 
Total 
Table 8d 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
February, 1993 
2nd LOT942 
DF SS MS EMS 
2 130461.63 65230.82 (} 2 5 2 2 Q ou = a E + 2.27 4as + l 3.652a n + P 
3 59.87 19.96 2 2 2 Bw = a E + 2.5557a 8 +15.334a 11 
30 510.80 17.03 Bw = a~ + 2.5029a~ 
17 427.05 25 .12 () 3u = a~ + 4 .0784a~ 
2 271.17 135 .58 
(}4u = a~ + 36a~ 
53 1281. 79 24.18 (} = a~ 
5 ' 
107 184596.67 
Table Se 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
August, 1993 
LOT 941 
Source of 
Variation DF SS MS EMS 
-...J 
-...J 
Pool 2 64700.33 323S0.16 (}OU = (Ji+ 2 .21160"~ + 1 J.0580"~ + Qp 
Round 3 11. 91 J.97 Ow = CJ~ + 2 .6237CJ~ + 13.119CJ~ 
Sample 24 292.06 12.17 ()2U = (Ji+ 2.34230"~ 
Machine 14 270.88 l9.3S (}3U = (Ji + 3.84640"~ 
Technician 2 2S .87 12.93 (} 4U = (Ji + 300"~ 
Strip Vial 4 1364.99 341.2S (}5U = ()~ + 8.54 JlCJ~ 
Error 40 602.05 IS.OS ()6 = () ~. 
Total 89 106640.10 
-...I 
00 
Source of 
Variation 
Pool 
Round 
Sample 
Machine 
Technician 
Strip Vial 
Error 
Total 
Table Sf 
Analysis of Variance with Type III Unweighted Sums of Squares 
for Unbalanced Two-Fold Nested Mixed Model 
August, 1993 
LOT 564 
DF SS MS EMS 
2 62788.17 31394.08 2 2 ~ 0 Bou = a E + 2.2116a s + 1 l.058a n + -P 
3 64.42 21.47 B1u = a~ + 2 .6237a~ + 13.1l9a~ 
24 492.95 20.54 Bw = a~ + 2.3423a~ 
14 550.03 39.29 B3u = a~+ 3.8464a!, 
2 51.67 25 .83 B4u = a~ + 30a~ 
4 203.11 50.78 B5u =a~+ 8.541 ta; 
40 656.81 16.42 ()6 =a~ 
89 96485.60 
....J 
'° 
Table 9a 
95% Confidence Intervals on Variance Components 
February, 1993 
1st LOT 941 
Variance Component Estimate Lower Bound 
Round 4.30 0.52 
Sample -4.74 -11.60 
Machine 1.51 -4.40 
Technician 9.63 1.98 
Error 28.92 20.37 
Total Variation 39.62 28.57 
Upper Bound 
76.5 
1.86 
12.89 
411.64 
44.28 
448.30 
00 
0 
Table 9b 
95% Confidence Intervals on Variance Components 
February, 1993 
2nd LOT 941 
Variance Component Estimate Lower Bound 
Round 3.65 0.34 
Sample -1 .63 -6.35 
Machine -0.55 -3 .73 
Technician 0.19 -0.43 
Error 19.8 13 .99 
Total Variation 21.47 16.44 
Upper Bound 
63 .87 
3.77 
4.93 
28 .76 
30.18 
88 .. 62 
Table 9c 
95% Confidence Intervals on Variance Components 
February, 1993 
1st LOT 942 
,, 
Variance Component Estimate Lower Bound Upper Bound 
00 
-
Round 0.65 -1.13 26.65 
Sample 1.75 -2.82 8.53 
Machine 1.29 -l.88 7.98 
Technician 6.54 1.42 276.07 
Error 16.48 I 1.64 25 . 12 
Total Variation 26.72 19.59 297.68 
00 
N 
Table 9d 
95% Confidence Intervals on Variance Components 
February, 1993 
2nd LOT 942 
Variance Component Estimate Lower Bound 
Round 0.20 -1.08 
Sample -2.86 -8.48 
Machine 0.23 . -3 .91 
Technician 3.09 0.31 
Error 24.18 17.08 
Total Variation 24.85 19.30 
Upper Bound 
16.93 
3.12 
8.01 
148.05 
36.85 
171.13 
00 
l..>J 
Table 9e 
95% Confidence Intervals on Variance Components 
August, 1993 
LOT 941 
Variance Component Estimate Lower Bound 
Round -0.60 -1 .60 
Sample -1 .23 -5 .79 
Machine 1.12 -2.31 
Technician -0.07 -0.53 
Strip Vial 38.19 12.51 
Error 15.05 10.14 
Total Variation 52.46 26.33 
Upper Bound 
3.26 
3.99 
8.63 
16.50 
328.08 
24.64 
343 .05 
00 
~ 
Table 9f 
95% Confidence Intervals on Variance Components 
August, 1993 
LOT 564 
Variance Component Estimate Lower Bound 
Round 0.03 -1 .98 
Sample 1.76 -3 .85 
Machine 5.95 0.46 
Technician 0.31 -0.42 
Strip Vial 4.03 -0.03 
Error 16.42 11 .07 
Total Variation 28.49 21 .03 
Upper Bound 
21 .04 
10.19 
21.11 
33.43 
47.09 
26.88 
89.19 
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Figure la: Bias vs. True Value 
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Figure 1 b: Bias vs. True Value 
February, 1993 Lot942 
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Figure 2a: Bias vs. True Value 
August, 1993 Lot 941 
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Figure lb: Bias vs. True Value 
August, 1993 Lot 943 
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Figure Ja: Bias vs. True Value 
August, 1993 Lot 941 
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Figure Jb: Bias vs. True Value 
August, 1993 Lot 564 
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Appendix A 
Figure 1 
Experimental Conditions 
FACE TO FACE 
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(Minimal education 
about cholesterol such as 
usual public screener) 
5 Worksites 
92 
AUTOMATED 
FEEDBACK 
(R1) 
5 Worksites 
5 Worksites 
Appendix A 
Figure 2 
Enzymatic Assay Method for Total Blood Cholesterol 
from : Allain CA, Poon LS . Enzymatic Determination of Total Serum Cholesterol. Clin 
Chem 1975; 20: 470-476. 
All samples analyzed for total cholesterol in the Lipid Metabolism Laboratory were 
assayed on a Gilford Impact 400 auto analyzer (Gilford Instruments, Oberlin, Ohio) using 
reagent supplied by Worthington Diagnostics (Cooper Biochemicals, Malvern, 
Pennsylvannia). Breifly, cholesteryl esters in serum are hydrolyzed by cholesteryl esterase 
to produce unesterified cholesterol and fatty acids. The unesterified cholesterol is 
oxidized to cholestem-3-one and hydrogen peroxide. A quinoneimine chromagen with an 
absorption maximum at 500 nm is produced when phenol is oxidatively coupled with 4-
amino antipyrine in the presence of hydrogen peroxide and the enzyme peroxidase. The 
absorbance is proportional to the amount of total cholesterol in the test sample. Primary 
cholesterol standards were obtained from the Center for Disease Control - Lipid 
Standardization Program which were used to calibrate large secondary serum pool 
standards for daily use in calibration of the Gilford Impact 400. Low, medium, and high 
cholesterol pools, generated from salvaged serum, were analyzed in each assay as well as a 
commercial serum-based control and a commercial aqueous standard. 
93 
Appendix B 
Figure 1 
Results of Initial Lot Testing 
February, 1993 
Lot 941 & 942 
Obs Lot 941 Lot 942 Miriam 
1 216 204 228 
2 231 222 227 
3 206 193 209 
4 214 211 224 
5 263 237 258 
6 188 158 176 
7 206 194 210 
8 146 137 149 
9 100 100 111 
10 148 146 154 
11 161 153 166 
12 207 193 206 
13 246 281 274 
14 219 247 243 
15 265 297 281 
16 151 157 160 
17 178 180 188 
18 224 230 235 
19 142 135 150 
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Appendix B 
Figure 2 
Results of Initial Lot Testing 
August, 1993 
Lot 941 & 943 
Obs Lot 941 Lot 943 Miriam 
1 213 183 219 
2 129 118 154 
3 220 200 223 
4 177 163 196 
5 273 243 271 
6 225 212 244 
7 281 264 292 
8 167 161 182 
9 162 155 173 
10 258 244 263 
11 160 154 
12 138 133 161 
13 187 173 196 
14 296 274 311 
15 114 115 135 
16 201 192 203 
17 204 184 207 
18 214 193 233 
19 175 168 200 
20 212 194 211 
21 244 244 276 
22 135 136 151 
23 132 147 157 
24 157 168 187 
25 202 201 216 
26 213 208 229 
27 188 185 198 
28 138 144 169 
29 171 162 177 
30 227 203 232 
31 227 232 248 
32 158 161 184 
33 166 184 198 
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Appendix B 
Figure 3 
Results oflnitial Lot Testing 
August, 1993 
Lot 941 & 564 
Obs Lot 941 Lot 564 Miriam 
1 209 218 223 
2 210 217 240 
3 133 137 156 
4 255 263 266 
5 156 171 186 
6 201 208 209 
7 196 205 221 
8 161 176 181 
9 231 243 246 
JO 220 224 233 
11 217 211 229 
12 220 219 238 
13 166 186 203 
14 195 197 213 
15 312 308 300 
16 159 174 188 
17 194 197 225 
18 171 176 204 
19 228 237 237 
20 155 172 182 
21 173 176 195 
22 182 180 202 
23 116 144 151 
24 121 131 151 
25 144 161 184 
26 167 168 189 
27 209 211 223 
28 233 231 243 
29 195 193 216 
30 227 225 240 
31 160 180 181 
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Appendix C 
Figure 1 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February,1993 
1st Lot 941 
obs tech seq round pool sample mach chol 
1 I 1 1 high 1 16 249 
2 1 2 high 2 13 243 
3 3 high 3 9 245 
4 1 4 1 high 4 18 248 
5 1 5 1 high 5 17 243 
6 1 6 1 high 6 10 244 
7 I 7 low 1 15 165 
8 I 8 I low 2 1 146 
9 9 1 low 3 2 154 
10 10 1 low 4 6 161 
11 1 11 1 low 5 7 163 
12 12 1 low 6 8 159 
13 13 1 med I 4 222 
14 1 14 med 2 5 230 
15 15 ) med 3 1 ) 223 
16 1 16 1 med 4 3 224 
17 1 17 1 med 5 14 221 
18 1 18 med 6 12 235 
19 1 1 2 low 1 8 165 
20 1 2 2 low 2 5 162 
21 1 3 2 low 3 4 165 
22 1 4 2 low 4 7 169 
23 1 5 2 low 5 13 166 
24 1 6 2 low 6 10 164 
25 1 7 2 med 1 6 225 
26 1 8 2 med 2 17 212 
27 1 9 2 med 3 11 210 
28 1 10 2 med 4 3 217 
29 1 11 2 med 5 14 216 
30 1 12 2 med 6 15 212 
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Appendix C 
Figure 1 (con't) 
·' 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February,1993 
1st Lot 941 
obs tech seq round pool sample mach chol 
31 1 13 2 high 1 9 242 
32 1 14 2 high 2 19 234 
33 15 2 high 3 18 231 
34 1 16 2 high 4 1 229 
35 1 17 2 high 5 12 237 
36 1 18 2 high 6 2 239 
37 2 1 med 1 11 212 
38 2 2 1 med 2 19 220 
39 2 3 med 3 6 214 
40 2 4 1 med 4 12 217 
41 2 5 1 med 5 14 214 
42 2 6 med 6 17 215 
43 2 7 high 1 15 238 
44 2 8 high 2 16 243 
45 2 9 high 3 2 237 
46 2 10 high 4 10 243 
47 2 11 high 5 5 243 
48 2 12 high 6 18 238 
49 2 13 1 low 1 3 154 
50 2 14 1 low 2 4 166 
51 2 15 1 low 3 7 157 
52 2 16 1 low 4 9 156 
53 2 17 1 low 5 13 154 
54 2 18 1 low 6 8 156 
55 2 1 2 high 1 16 238 
56 2 2 2 high 2 2 243 
57 2 3 2 high 3 3 237 
58 2 4 2 high 4 19 237 
59 2 5 2 high 5 1 234 
60 2 6 2 high 6 11 237 
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Appendix C 
Figure 1 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 941 
obs tech seq round pool sample ma ch chol 
61 2 7 2 low 1 14 154 
62 2 8 2 low 2 4 156 
63 2 9 2 low 3 10 155 
64 2 10 2 low 4 18 151 
65 2 11 2 low 5 13 156 
66 2 12 2 low 6 9 154 
67 2 13 2 med 1 17 216 
68 2 14 2 med 2 5 213 
69 2 15 2 med 3 6 217 
70 2 16 2 med 4 7 214 
71 2 17 2 med 5 15 214 
72 2 18 2 med 6 12 217 
73 3 1 low 1 6 146 
74 3 2 low 2 11 149 
75 3 3 low 3 16 149 
76 3 4 1 low 4 8 148 
77 3 5 1 low 5 1 149 
78 3 6 low 6 17 156 
79 3 7 1 med 1 12 213 
80 3 8 1 med 2 19 216 
81 3 9 med 3 5 207 
82 3 10 1 med 4 7 207 
83 3 11 1 med 5 4 211 
84 3 12 1 med 6 9 217 
85 3 13 1 high 1 15 240 
86 3 14 1 high 2 3 235 
87 3 15 1 high 3 2 239 
88 3 16 1 high 4 IO 236 
89 3 17 1 high 5 18 231 
90 3 18 1 high 6 13 239 
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Appendix C 
Figure 1 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 941 
obs tech seq round pool sample ma ch chol 
91 3 1 2 med 1 12 207 
92 3 2 2 med 2 6 209 
93 3 3 2 med 3 14 205 
94 3 4 2 med 4 1 204 
95 3 5 2 med 5 19 219 
96 3 6 2 med 6 15 216 
97 3 7 2 high 1 7 245 
98 3 8 2 high 2 2 234 
99 3 9 2 high 3 9 238 
100 3 10 2 high 4 18 229 
101 3 11 2 high 5 17 240 
102 3 12 2 high 6 5 250 
103 3 13 2 low 1 11 159 
104 3 14 2 low 2 13 166 
105 3 15 2 low 3 10 158 
106 3 16 2 low 4 3 159 
107 3 17 2 low 5 4 169 
108 3 18 2 low 6 8 152 
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Appendix C 
Figure 2 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 941 
obs tech seq round tube pool sample mach chol 
1 1 1 3 1 high 1 12 239 
2 2 3 1 high 2 16 231 
3 1 3 3 1 high 3 10 235 
4 1 4 3 1 high 4 21 244 
5 1 5 3 1 high 5 8 235 
6 6 3 1 high 6 9 234 
7 1 7 3 2 med 1 17 214 
8 1 8 3 2 med 2 5 214 
9 1 9 3 2 med 3 3 211 
10 1 10 3 2 med 4 11 209 
11 11 3 2 med 5 18 210 
12 12 3 2 med 6 4 218 
13 13 3 3 low 1 15 147 
14 14 3 3 low 2 7 155 
15 15 3 3 . low 3 14 151 
16 16 3 3 low 4 20 155 
17 1 17 3 3 low 5 19 151 
18 1 18 3 3 low 6 6 152 
19 1 19 4 4 med 1 14 216 
20 20 4 4 med 2 20 217 
21 1 21 4 4 med 3 16 215 
22 1 22 4 4 med 4 10 214 
23 1 23 4 4 med 5 17 216 
24 24 4 4 med 6 18 214 
25 1 25 4 5 low 1 7 149 
26 1 26 4 5 low 2 19 148 
27 1 27 4 5 low 3 6 148 
28 1 28 4 5 low 4 5 152 
29 1 29 4 5 low 5 12 165 
30 30 4 5 low 6 3 153 
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Appendix C 
Figure 2 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 941 
obs tech seq round tube pool sample mach chol 
31 1 31 4 6 high 1 21 247 
32 1 32 4 6 high 2 4 243 
33 1 33 4 6 high 3 8 241 
34 1 34 4 6 high 4 9 244 
35 35 4 6 high 5 11 241 
36 1 36 4 6 high 6 15 247 
37 2 1 3 1 med 1 7 213 
38 2 2 3 1 med 2 4 217 
39 2 3 3 1 med 3 6 206 
40 2 4 3 1 med 4 17 212 
41 2 5 3 1 med 5 9 218 
42 2 6 3 1 med 6 18 209 
43 2 7 3 2 low 1 20 157 
44 2 8 3 2 low 2 5 156 
45 2 9 3 2 low 3 8 148 
46 2 10 3 2 low 4 3 148 
47 2 11 3 2 low 5 21 152 
48 2 12 3 2 low 6 12 155 
49 2 13 3 3 high 1 14 235 
50 2 14 3 3 high 2 15 236 
51 2 15 3 3 high 3 16 230 
52 2 16 3 3 high 4 11 234 
53 2 17 3 3 high 5 19 233 
54 2 18 3 3 high 6 10 235 
55 2 19 4 4 low 1 15 153 
56 2 20 4 4 low 2 3 160 
57 2 21 4 4 low 3 8 144 
58 2 22 4 4 low 4 7 146 
59 2 23 4 4 low 5 14 153 
60 2 24 4 4 low 6 21 146 
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Appendix C 
Figure 2 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 941 
obs tech seq round tube pool sample mach chol 
61 2 25 4 5 high 1 16 246 
62 2 26 4 5 high 2 4 235 
63 2 27 4 5 high 3 5 232 
64 2 28 4 5 high 4 17 237 
65 2 29 4 5 high 5 20 233 
66 2 30 4 5 high 6 18 235 
67 2 31 4 6 med I 6 224 
68 2 32 4 6 med 2 10 218 
69 2 33 4 6 med 3 12 223 
70 2 34 4 6 med 4 9 219 
71 2 35 4 6 med 5 19 225 
72 2 36 4 6 med 6 11 219 
73 3 1 3 low 1 15 158 
74 3 2 3 low 2 18 154 
75 3 3 3 low 3 9 150 
76 3 4 3 1 low 4 3 152 
77 3 5 3 1 low 5 8 152 
78 3 6 3 1 low 6 21 149 
79 3 7 3 2 high 1 12 244 
80 3 8 3 2 high 2 7 235 
81 3 9 3 2 high 3 6 232 
82 3 10 3 2 high 4 16 231 
83 3 11 3 2 high 5 14 237 
84 3 12 3 2 high 6 I I 234 
85 3 13 3 3 med 1 5 220 
86 3 14 3 3 med 2 19 212 
87 3 15 3 3 med 3 17 212 
88 3 16 3 3 med . 4 20 211 
89 3 17 3 3 med 5 4 211 
90 3 18 3 3 med 6 10 209 
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Appendix C 
Figure 2 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 941 
obs tech seq round tube pool sample ma ch chol 
91 3 19 4 4 high 1 3 233 
92 3 20 4 4 high 2 18 239 
93 3 21 4 4 high 3 14 234 
94 3 22 4 4 high 4 5 239 
95 3 23 4 4 high 5 6 233 
96 3 24 4 4 high 6 19 233 
97 3 25 4 5 med 1 9 211 
98 3 26 4 5 med 2 11 208 
99 3 27 4 5 med 3 4 214 
100 3 28 4 5 med 4 12 216 
101 3 29 4 5 med 5 20 216 
102 3 30 4 5 med 6 16 213 
103 3 31 4 6 low 1 17 155 
104 3 32 4 6 low 2 10 155 
105 3 33 4 6 low 3 21 150 
106 3 34 4 6 low 4 8 156 
107 3 35 4 6 low 5 15 153 
108 3 36 4 6 low 6 7 152 
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Appendix C 
Figure 3 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 942 
obs tech seq round tube pool sample ma ch chol 
1 1 1 1 1 high 1 12 243 
2 2 1 1 high 2 16 242 
3 1 3 1 1 high 3 10 245 
4 1 4 1 high 4 2 237 
5 1 5 1 1 high 5 8 241 
6 1 6 1 1 high 6 9 249 
7 1 7 1 2 med 1 17 219 
8 1 8 1 2 med 2 5 213 
9 1 9 1 2 med 3 3 219 
10 1 10 1 2 med 4 11 241 
11 1 11 1 2 med 5 18 218 
12 1 12 1 2 med 6 4 228 
13 13 l 3 low 1 15 151 
14 1 14 1 3 low 2 7 145 
15 15 1 3 low 3 14 152 
16 16 1 3 low 4 1 153 
17 1 17 3 low 5 13 149 
18 1 18 1 3 low 6 6 151 
19 1 19 2 4 med 1 14 221 
20 1 20 2 4 med 2 1 222 
21 21 2 4 med 3 16 217 
22 1 22 2 4 med 4 10 219 
23 1 23 2 4 med 5 17 219 
24 1 24 2 4 med 6 18 218 
25 1 25 2 5 low 1 7 152 
26 1 26 2 5 low 2 13 148 
27 1 27 2 5 low 3 6 149 
28 1 28 2 5 low 4 5 150 
29 1 29 2 5 low 5 12 153 
30 1 30 2 5 low 6 3 150 
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Appendix C 
Figure 3 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 942 
obs tech seq round tube pool sample ma ch chol 
31 1 31 2 6 high 1 2 240 
32 1 32 2 6 high 2 4 245 
33 33 2 6 high 3 8 233 
34 1 34 2 6 high 4 9 240 
35 35 2 6 high 5 11 236 
36 1 36 2 6 high 6 15 239 
37 2 1 1 1 med 1 7 219 
38 2 2 l 1 med 2 4 221 
39 2 3 1 1 med 3 6 220 
40 2 4 1 1 med 4 17 223 
41 2 5 1 1 med 5 9 216 
42 2 6 1 1 med 6 18 220 
43 2 7 2 low 1 1 156 
44 2 8 1 2 low 2 5 151 
45 2 9 1 2 low 3 8 154 
46 2 10 1 2 low 4 3 149 
47 2 11 2 low 5 2 155 
48 2 12 1 2 low 6 12 158 
49 2 13 3 high 1 14 235 
50 2 14 3 high 2 15 244 
51 2 15 1 3 high 3 16 239 
52 2 16 1 3 high 4 11 253 
53 2 17 1 3 high 5 13 234 
54 2 18 1 3 high 6 10 241 
55 2 19 2 4 low 1 15 148 
56 2 20 2 4 low 2 3 149 
57 2 21 2 4 low 3 8 146 
58 2 22 2 4 low 4 7 151 
59 2 23 2 4 low 5 14 142 
60 2 24 2 4 low 6 2 151 
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Figure 3 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 942 
obs tech seq round tube pool sample ma ch chol 
61 2 25 2 5 high 1 16 241 
62 2 26 2 5 high 2 4 238 
63 2 27 2 5 high 3 5 242 
64 2 28 2 5 high 4 17 239 
65 2 29 2 5 high 5 1 237 
66 2 30 2 5 high 6 18 240 
67 2 31 2 6 med 1 6 215 
68 2 32 2 6 med 2 10 217 
69 2 33 2 6 med 3 12 213 
70 2 34 2 6 med 4 9 216 
71 2 35 2 6 med 5 13 214 
72 2 36 2 6 med 6 11 221 
73 3 1 1 1 low 1 15 156 
74 3 2 1 1 low 2 18 150 
75 3 3 1 1 low 3 9 156 
76 3 4 1 1 low 4 3 153 
77 3 5 1 1 low 5 8 157 
78 3 6 1 1 low 6 2 154 
79 3 7 1 2 high 1 12 245 
80 3 8 1 2 high 2 7 243 
81 3 9 1 2 high 3 6 249 
82 3 10 1 2 high 4 16 243 
83 3 11 2 high 5 14 238 
84 3 12 1 2 high 6 11 254 
85 3 13 1 3 med 1 5 224 
86 3 14 1 3 med 2 13 215 
87 3 15 1 3 med 3 17 221 
88 3 16 1 3 med 4 1 231 
89 3 17 1 3 med 5 4 227 
90 3 18 1 3 med 6 10 220 
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Figure 3 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
1st Lot 942 
obs tech seq round tube pool sample mach chol 
91 3 19 2 4 high 1 3 248 
92 3 20 2 4 high 2 18 256 
93 3 21 2 4 high 3 14 251 
94 3 22 2 4 high 4 5 250 
95 3 23 2 4 high 5 6 247 
96 3 24 2 4 high 6 13 247 
97 3 25 2 5 med 9 216 
98 3 26 2 5 med 2 11 224 
99 3 27 2 5 med 3 4 227 
100 3 28 2 5 med 4 12 222 
101 3 29 2 5 med 5 1 224 
102 3 30 2 5 med 6 16 225 
103 3 31 2 6 low 1 17 152 
104 3 32 2 6 low 2 10 150 
105 3 33 2 6 low 3 2 152 
106 3 34 2 6 low 4 8 154 
107 3 35 2 6 low 5 15 157 
108 3 36 2 6 low 6 7 151 
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Figure 4 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 942 
obs tech seq round tube pool sample mach chol 
1 1 1 1 1 high 1 12 247 
2 1 2 1 I high 2 16 252 
3 3 1 high 3 10 241 
4 I 4 1 high 4 2 247 
5 1 5 1 1 high 5 8 244 
6 1 6 1 1 high 6 9 245 
7 1 7 2 med 1 17 221 
8 1 8 1 2 med 2 5 238 
9 1 9 1 2 med 3 3 216 
10 1 10 1 2 med 4 11 221 
11 11 2 med 5 18 231 
12 12 1 2 med 6 4 223 
13 I 13 1 3 low 1 15 151 
14 14 3 low 2 7 148 
15 15 1 3 low 3 14 154 
16 16 1 3 low 4 1 154 
17 17 1 3 low 5 13 152 
18 18 1 3 low 6 6 154 
19 1 19 2 4 med 1 14 222 
20 1 20 2 4 med 2 1 221 
21 1 21 2 4 med 3 16 214 
22 1 22 2 4 med 4 10 227 
23 1 23 2 4 med 5 17 220 
24 24 2 4 med 6 18 225 
25 1 25 2 5 low 1 7 147 
26 1 26 2 5 low 2 13 155 
27 1 27 2 5 low 3 6 148 
28 28 2 5 low 4 5 151 
29 1 29 2 5 low 5 12 159 
30 1 30 2 5 low 6 3 152 
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Figure 4 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 942 
obs tech seq round tube pool sample ma ch chol 
31 1 31 2 6 high 1 2 244 
32 1 32 2 6 high 2 4 255 
33 33 2 6 high 3 8 255 
34 1 34 2 6 high 4 9 250 
35 1 35 2 6 high 5 11 241 
36 I 36 2 6 high 6 15 260 
37 2 1 I 1 med 1 7 214 
38 2 2 1 1 med 2 4 228 
39 2 3 1 1 med 3 6 219 
40 2 4 1 I med 4 17 223 
41 2 5 1 1 med 5 9 218 
42 2 6 1 med 6 18 218 
43 2 7 1 2 low 1 1 155 
44 2 8 1 2 low 2 5 148 
45 2 9 1 2 low 3 8 155 
46 2 10 1 2 low 4 3 149 
47 2 11 1 2 low 5 2 153 
48 2 12 1 2 low 6 12 156 
49 2 13 1 3 high 1 14 246 
50 2 14 1 3 high 2 15 249 
51 2 15 3 high 3 16 255 
52 2 16 3 high 4 11 246 
53 2 17 1 3 high 5 13 244 
54 2 18 1 3 high 6 10 247 
55 2 19 2 4 low 1 15 151 
56 2 20 2 4 low 2 3 151 
57 2 21 2 4 low 3 8 153 
58 2 22 2 4 low 4 7 149 
59 2 23 2 4 low 5 14 151 
60 2 24 2 4 low 6 2 150 
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Figure 4 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 942 
obs tech seq round tube pool sample ma ch chol 
61 2 25 2 5 high 1 16 259 
62 2 26 2 5 high 2 4 246 
63 2 27 2 5 high 3 5 243 
64 2 28 2 5 high 4 17 254 
65 2 29 2 5 high 5 1 245 
66 2 30 2 5 high 6 18 242 
67 2 31 2 6 med 1 6 227 
68 2 32 2 6 med 2 10 222 
69 2 33 2 6 med 3 12 233 
70 2 34 2 6 med 4 9 218 
71 2 35 2 6 med 5 13 224 
72 2 36 2 6 med 6 11 226 
73 3 1 1 1 low 1 15 160 
74 3 2 1 1 low 2 18 150 
75 3 3 1 low 3 9 154 
76 3 4 1 low 4 3 157 
77 3 5 1 low 5 8 153 
78 3 6 1 1 low 6 2 159 
79 3 7 1 2 high 1 12 264 
80 3 8 2 high 2 7 248 
81 3 9 1 2 high 3 6 253 
82 3 10 1 2 high 4 16 253 
83 3 11 1 2 high 5 14 241 
84 3 12 1 2 high 6 11 245 
85 3 13 3 med 1 5 232 
86 3 14 1 3 med 2 13 219 
87 3 15 1 3 med 3 17 226 
88 3 16 1 3 med 4 1 231 
89 3 17 1 3 med 5 4 228 
90 3 18 1 3 med 6 10 225 
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Figure 4 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
February, 1993 
2nd Lot 942 
obs tech seq round tube pool sample ma ch chol 
91 3 19 2 4 high 1 3 256 
92 3 20 2 4 high 2 18 259 
93 3 21 2 4 high 3 14 249 
94 3 22 2 4 high 4 5 257 
95 3 23 2 4 high 5 6 248 
96 3 24 2 4 high 6 13 249 
97 3 25 2 5 med 1 9 225 
98 3 26 2 5 med 2 11 228 
99 3 27 2 5 med 3 4 231 
100 3 28 2 5 med 4 12 226 
101 3 29 2 5 med 5 1 230 
102 3 30 2 5 med 6 16 226 
103 3 31 2 6 low 1 17 152 
104 3 32 2 6 low 2 10 157 
105 3 33 2 6 low 3 2 153 
106 3 34 2 6 low 4 8 149 
107 3 35 2 6 low 5 15 155 
108 3 36 2 6 low 6 7 148 
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Figure 5 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 941 
obs tech seq round tube pool sample ma ch strvial chol 
1 1 1 1 1 low 1 13 4 143 
2 1 2 1 low 2 15 1 146 
3 1 3 1 low 3 8 5 155 
4 1 4 1 low 4 3 2 139 
5 1 5 1 1 low 5 7 3 142 
6 1 6 1 2 high 1 2 5 241 
7 1 7 1 2 high 2 11 2 225 
8 1 8 1 2 high 3 5 4 219 
9 1 9 1 2 high 4 6 1 224 
10 1 10 1 2 high 5 14 3 234 
11 1 11 1 3 med 1 1 1 211 
12 1 12 1 3 med 2 4 4 202 
13 1 13 1 3 med 3 12 3 209 
14 1 14 1 3 med 4 IO 5 211 
15 1 15 1 3 med 5 9 2 198 
16 1 16 2 4 high 1 6 5 234 
17 1 17 2 4 high 2 13 1 231 
18 1 18 2 4 high 3 i2 4 218 
19 1 19 2 4 high 4 5 3 233 
20 1 20 2 4 high 5 15 2 213 
21 1 21 2 5 med 1 2 1 212 
22 1 22 2 5 med 2 7 2 196 
23 1 23 2 5 med 3 8 4 199 
24 1 24 2 5 med 4 1 5 217 
25 1 25 2 5 med 5 11 3 207 
26 1 26 2 6 low 1 3 5 154 
27 1 27 2 6 low 2 9 1 152 
28 1 28 2 6 low 3 10 3 152 
29 1 29 2 6 low 4 14 4 143 
30 1 30 2 6 low 5 4 2 141 
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Figure 5 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 941 
obs tech seq round tube pool sample mach strvial chol 
31 2 1 1 1 med 1 12 2 194 
32 2 2 1 1 med 2 10 5 220 
33 2 3 1 1 med 3 13 3 218 
34 2 4 I 1 med 4 7 1 202 
35 2 5 1 1 med 5 11 4 213 
36 2 6 1 2 low 1 1 1 147 
37 2 7 1 2 low 2 2 4 155 
38 2 8 1 2 low 3 9 5 155 
39 2 9 1 2 low 4 4 2 140 
40 2 10 1 2 low 5 15 3 147 
41 2 11 1 3 high 1 6 1 232 
42 2 12 1 3 high 2 8 5 232 
43 2 13 1 3 high 3 3 3 228 
44 2 14 I 3 high 4 14 2 218 
45 2 15 1 3 high 5 5 4 223 
46 2 16 2 4 low 1 15 1 147 
47 2 17 2 4 low 2 13 3 155 
48 2 18 2 4 low 3 4 5 153 
49 2 19 2 4 low 4 7 2 141 
50 2 20 2 4 low 5 3 4 146 
51 2 21 2 5 high 1 9 1 232 
52 2 22 2 5 high 2 10 5 238 
53 2 23 2 5 high 3 11 3 227 
54 2 24 2 5 high 4 14 4 219 
55 2 25 2 5 high 5 6 2 212 
56 2 26 2 6 med 1 8 2 200 
57 2 27 2 6 med 2 2 5 212 
58 2 28 2 6 med 3 12 4 204 
59 2 29 2 6 med 4 1 3 210 
60 2 30 2 6 med 5 5 1 209 
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Figure 5 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 941 
obs tech seq round tube pool sample mach strvial chol 
61 3 1 1 1 high 1 13 4 219 
62 3 2 1 high 2 1 5 240 
63 3 3 1 high 3 10 3 226 
64 3 4 1 1 high 4 14 2 223 
65 3 5 1 1 high 5 11 1 230 
66 3 6 1 2 med 1 4 1 213 
67 3 7 1 2 med 2 5 4 201 
68 3 8 2 med 3 2 3 209 
69 3 9 1 2 med 4 15 2 199 
70 3 10 2 med 5 8 5 216 
71 3 11 3 low 1 3 5 154 
72 3 12 3 low 2 7 3 145 
73 3 13 1 3 low 3 6 2 141 
74 3 14 1 3 low 4 9 4 141 
75 3 15 1 3 low 5 12 1 154 
76 3 16 2 4 med 1 13 4 207 
77 3 17 2 4 med 2 5 2 203 
78 3 18 2 4 med 3 6 1 208 
79 3 19 2 4 med 4 14 3 219 
80 3 20 2 4 med 5 2 5 219 
81 3 21 2 5 low 1 7 2 142 
82 3 22 2 5 low 2 8 3 155 
83 3 23 2 5 low 3 15 5 153 
84 3 24 2 5 low 4 1 4 139 
85 3 25 2 5 low 5 12 1 153 
86 3 26 2 6 high 1 4 2 219 
87 3 27 2 6 high 2 11 4 218 
88 3 28 2 6 high 3 9 1 229 
89 3 29 2 6 high 4 10 3 230 
90 3 30 2 6 high 5 3 5 234 
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Figure 6 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 564 
obs tech seq round tube pool sample mach strvial chol 
1 1 1 1 1 low 1 13 4 161 
2 1 2 1 1 low 2 15 1 152 
3 1 3 1 1 low 3 8 5 150 
4 1 4 1 low 4 3 2 153 
5 1 5 1 low 5 7 3 156 
6 1 6 2 high 1 2 5 224 
7 1 7 1 2 high 2 11 2 226 
8 1 8 1 2 high 3 5 4 232 
9 1 9 1 2 high 4 6 1 240 
10 1 10 1 2 high 5 14 3 230 
11 1 11 1 3 med 1 1 1 214 
12 1 12 3 med 2 4 4 215 
13 13 1 3 med 3 12 3 226 
14 1 14 l 3 med 4 10 5 203 
15 1 15 1 3 med 5 9 2 204 
16 1 16 2 4 high 1 6 5 229 
17 1 17 2 4 high 2 13 1 229 
18 1 18 2 4 high 3 12 4 240 
19 1 19 2 4 high 4 5 3 231 
20 1 20 2 4 high 5 15 2 230 
21 1 21 2 5 med 1 2 1 206 
22 1 22 2 5 med 2 7 2 209 
23 1 23 2 5 med 3 8 4 212 
24 1 24 2 5 med 4 1 5 203 
25 1 25 2 5 med 5 11 3 211 
26 1 26 2 6 low 1 3 5 154 
27 1 27 2 6 low 2 9 1 158 
28 1 28 2 6 low 3 IO 3 152 
29 1 29 2 6 low 4 14 4 157 
30 1 30 2 6 low 5 4 2 156 
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Figure 6 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 564 
obs tech seq round tube pool sample ma ch strvial chol 
31 2 1 1 1 med 1 12 2 217 
32 2 2 1 1 med 2 10 5 211 
33 2 3 1 1 med 3 13 3 211 
34 2 4 1 1 med 4 7 1 211 
35 2 5 1 1 med 5 11 4 213 
36 2 6 1 2 low 1 1 1 153 
37 2 7 1 2 low 2 2 4 155 
38 2 8 1 2 low 3 9 5 154 
39 2 9 1 2 low 4 4 2 155 
40 2 10 1 2 low 5 15 3 156 
41 2 11 1 3 high 1 6 1 230 
42 2 12 1 3 high 2 8 5 230 
43 2 13 1 3 high 3 3 3 237 
44 2 14 1 3 high 4 14 2 227 
45 2 15 1 3 high 5 5 4 230 
46 2 16 2 4 low 1 15 1 156 
47 2 17 2 4 low 2 13 3 155 
48 2 18 2 4 low 3 4 5 152 
49 2 19 2 4 low 4 7 2 152 
50 2 20 2 4 low 5 3 4 157 
51 2 21 2 5 high 1 9 1 234 
52 2 22 2 5 high 2 10 5 223 
53 2 23 2 5 high 3 11 3 230 
54 2 24 2 5 high 4 14 4 228 
55 2 25 2 5 high 5 6 2 238 
56 2 26 2 6 med 1 8 2 223 
57 2 27 2 6 med 2 2 5 206 
58 2 28 2 6 med 3 12 4 212 
59 2 29 2 6 med 4 1 3 221 
60 2 30 2 6 med 5 5 1 206 
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Figure 6 (con't) 
Precision Experiment Generated By Proc Plan 
& Cholesterol Results 
August, 1993 
Lot 564 
obs tech seq round tube pool sample mach strvial chol 
61 3 1 1 1 high 1 13 4 232 
62 3 2 I high 2 5 219 
63 3 3 1 1 high 3 10 3 235 
64 3 4 1 1 high 4 14 2 226 
65 3 5 I 1 high 5 11 1 239 
66 3 6 1 2 med 1 4 1 228 
67 3 7 I 2 med 2 5 4 213 
68 3 8 1 2 med 3 2 3 217 
69 3 9 1 2 med 4 15 2 208 
70 3 10 2 med 5 8 5 207 
71 3 11 3 low 1 3 5 153 
72 3 12 1 3 low 2 7 3 151 
73 3 13 1 3 low 3 6 2 151 
74 3 14 1 3 low 4 9 4 152 
75 3 15 1 3 low 5 12 1 159 
76 3 16 2 4 med 1 13 4 214 
77 3 17 2 4 med 2 5 2 210 
78 3 18 2 4 med 3 6 1 221 
79 3 19 2 4 med 4 14 3 217 
80 3 20 2 4 med 5 2 5 213 
81 3 21 2 5 low 1 7 2 154 
82 3 22 2 5 low 2 8 3 163 
83 3 23 2 5 low 3 15 5 153 
84 3 24 2 5 low 4 1 4 160 
85 3 25 2 5 low 5 12 1 163 
86 3 26 2 6 high 1 4 2 225 
87 3 27 2 6 high 2 11 4 236 
88 3 28 2 6 high 3 9 1 235 
89 3 29 2 6 high 4 10 3 238 
90 3 30 2 6 high 5 3 5 226 
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